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Increasing evidence suggests that virus-specific CD4+ T cells contribute to immune-mediated 
control of HIV-1 infection. However, precise details of CD4+ T cell contribution to immune 
protection against HIV have not been adequately defined and most of the existing data was 
predominantly generated in clade B HIV-1 infection. Understanding the contribution of 
CD4+ T cell responses in clade C infection is important for developing vaccines that would 
be efficacious in sub-Saharan Africa which carries the highest burden of the HIV epidemic in 
the world. Therefore this study focused on the role of CD4+ T helper cells in the immune 
response to clade C HIV-1 infection. We tested the hypothesis that HIV-1-specific CD4+ T 
cell responses and protective class II HLA alleles are important determinants of effective 
immunological control of HIV-1 infection.  
Firstly, CD8 depleted PBMCs were used in an IFN-γ ELISPOT assay to conduct a 
comprehensive analysis of virus-specific CD4+ T cell responses in acute and chronic HIV-1 
clade C infection. Thereafter the host genetic effects of class II HLA-DRB1 alleles on HIV 
viremia were assessed using the HLA-DRB1 restriction assay, where HLA class II-restriction 
characteristics of detectable responses were defined. Lastly, functional differences of HIV-
specific CD4+ T cells were further characterized using flow cytometric analysis. 
In our study, Gag and Pol regions of the HIV proteome were found to be the most frequently 
targeted in acute HIV-1 infection (69% of total responses), with CD4+ T cell targeting across 
the proteome remaining relatively stable over time. In chronic HIV-1 clade C infection, 
dominant HIV-1-specific CD4+ T cell responses were detectable against a limited number of 
epitopes. Epitopes in the Gag region were the most targeted by CD4+ T cells (30/40 
peptides), with OLP 41 in the Gag p24 region being the most dominant epitope targeted (15% 
of responses). There were no significant differences observed between total or Gag-specific 
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CD4+ T cell responses and contemporaneous viral load. Interestingly, responses rarely 
targeted the envelope region in clade C infection, in contrast to multiple epitopes targeted in 
this protein in previous clade B studies. Functional analysis demonstrated that IFN-γ, IL-2 
and TNFα were the most secreted cytokines by HIV-specific CD4+ T cells in 18/25 
individuals, with IFN-γ being the most dominant response in individual subjects. The HLA 
class II DRB1 restriction in clade C HIV infected individuals showed epitope promiscuity, 
consistent with previous studies in clade B infection. The HLA-DRB1*13:01 allele variant 
was associated with the highest frequency of responders (22%) in our cohort and restricted 
the highest number of HIV-specific peptides (9/15). 
Together, our data identify immunodominant regions of HIV-specific CD4+ T cell responses 
and their association with viral control during clade C infection. Furthermore, our findings 
will inform studies aimed at elucidating the underlying mechanism by which CD4+ T cells 
modulate effective CD8+ T cell and B cell responses. Additionally, these data suggest that 
epitope promiscuity among class II HLA molecules should be taken into account for vaccines 
designed to induce CD4+ T cell responses. This information will be critical to vaccine efforts 
designed to induce these responses, as well as potential therapeutic manipulation of immunity 
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CHAPTER 1: LITERATURE REVIEW 
1.1 THE HIV-1 EPIDEMIC 
The Human Immunodeficiency Virus (HIV), discovered in 1983, is the pathogen responsible 
for Acquired Immune Deficiency Syndrome (AIDS), which has fast established itself as a 
global pandemic (BarreSinoussi, 1996). The first clinical observance of AIDS was made in 
1981 in the United States amongst injecting drug users and homosexual men with no known 
cause of weakened immunity. They presented with symptoms of Pneumocystis pneumonia 
and Kaposi’s sarcoma, with both diseases previously being rare infections occurring only in 
people with very compromised immune systems (Barre-Sinoussi et al., 2013, Urmacher et al., 
1982, Janier et al., 1984, Gottlieb et al., 1981). There was no official name for the disease 
with various terms being coined, one of which being GRID, which stood for gay-related 
immune deficiency. It soon became apparent that this disease was not limited to specific 
population groups and in 1982 the term AIDS was introduced. A lentivirus with close relation 
to the human T-lymphotropic virus (HTLV) was identified as the aetiological agent  of the 
disease and later named HIV (Montagnier, 2002). AIDS is characterized by a conspicuous 
reduction of CD4+ T cells and ultimately a failure of the immune system to contain virus 
replication, leading to increased susceptibility to opportunistic infections and finally death 
(Fauci, 2008). 
1.2 PREVALENCE 
HIV continues to be a major global public health issue, having claimed more than 39 million 
lives so far. According to the World Health Organization, an estimated 35 million people 
globally were living with HIV-infection at the end of 2013, sub-Saharan Africa being the 
most affected region, with 24.7 million people living with HIV in 2013. In that same year, 2.1 
million people became newly infected with the virus and 1.5 million people died from HIV-
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related causes globally (UNAIDS, 2012). Currently there is no cure for HIV-1 infection; 
however, effective treatment with antiretroviral therapy (ART) can control the virus to enable 
people living with HIV to enjoy healthier and more productive lives. In 2013, 12.9 million 
people living with HIV were receiving ART globally, many of whom were from low to 
middle income countries. Access to treatment is still lower in children, where 1 in 4 children 
living with HIV have access to treatment as compared to 1 in 3 adults (UNAIDS, 2012). 
Arguably, prophylactic vaccination will be the most effective way of controlling the epidemic 
because of the cost and complexity of other preventative methods available, and because 
other currently available methods only slow down the replication or spread of the virus, while 
failing to clear it from the body and completely stop the spread to other people. 
1.3 HIV GENETIC DIVERSITY 
One of the major challenges for developing an efficacious HIV vaccine is the intrinsic 
diversity among circulating populations of HIV-1 in various geographical locations and the 
need to develop vaccines that can elicit enduring protective immunity across different strains. 
Varied levels of sequence diversity of the viral genome across all regions have been found 
through molecular analysis of HIV isolates. Sequence diversity of HIV can occur in 
numerous ways, these include, recombination, insertions and deletions, gain or loss of 
glycosylation sites and simple base substitutions (Fauci, 2008). There are three major groups 
of HIV-1 which represent separate introductions of the virus into humans from simians, with 
a fourth one being proposed recently  (Van Heuverswyn and Peeters, 2007). The groups are 
M (main), N( new) and O (outlier) and P. Group M, responsible for most of the infections in 
the world comprises of nine subtypes, which are labelled as A, B, C, D, F, G, H, J and K , as 
well as an increasing number of both major and minor circulating recombinant forms (CRFs), 
with the strain previously referred to as subtype E, being the most common (Van 
Heuverswyn and Peeters, 2007) (Figure 1.1). CRFs are formed through a recombination and 
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creation of a virus with selective advantage by an individual infected with two subtypes. 
Subtype A and F of Group M have been further differentiated into sub-subtypes A1 and A2, 
and F1 and F2, respectively. Pan troglodytes troglodytes, is the chimpanzee subspecies 
identified as the natural reservoir of the M and N groups of HIV-1 (Julg et al., 2010). The 
HIV-1 O group, a fairly rare form of the virus originating in France, Gabon and Cameroon is 
shown to be most closely related to viruses found in Cameroonian gorillas.  
Subtype C viruses account for more than 50% of infections globally, with majority of 
infections caused by subtype C being in sub-Saharan Africa, which carries the highest burden 
of two-thirds of all individuals living with the disease (Maenetje et al., 2010, Hemelaar, 
2012).  
The astonishing diversity of HIV, which is observed by the existence of numerous subtypes, 
circulating recombinant forms and the continuous evolution of the virus, poses a formidable 
hindrance to HIV vaccine development, where varied rates of disease progression, resistance 






1.4 MOLECULAR BIOLOGY OF HIV-1 
1.4.1 STRUCTURE AND ORGANIZATION OF THE HIV-1 GENOME 
HIV is an enveloped, single stranded RNA virus belonging to the genus Lentivirus of the 
Retroviridae family (BarreSinoussi, 1996). The HIV virion is spherical in shape, with a 
diameter of 1/10,000 of a millimetre. HIV, like other retroviruses contains a viral capsid, 
which includes the major capsid protein, Gag p24;the nucleocapsid protein p7/p9, the diploid 
single-stranded RNA genome, and the viral enzymes protease, reverse transcriptase, and 
integrase (Lever, 2009) (Figure 1.2). The viral capsid can be broken into three parts, viz. the 
viral envelope, the core and the matrix protein that lies between the two aforementioned 
Figure 1.1. Worldwide distribution and genetic diversity of the major clades and recombinants  




parts. The viral envelope is a phospholipid bilayer, which is derived from host cell 
membrane, which includes virally encoded membrane proteins (BarreSinoussi, 1996).  
Approximately 72 copies of envelope glycoprotein complex form the spikes on the virus' 
surface (Gelderblom, 1991). Surface protein, gp 120 makes up the cap of the spike, while 
transmembrane protein, gp 41 makes up the stem of each spike. The layer below the viral 
envelope is known as the matrix, which is made up from protein Gag p17. The viral core, 
made up of Gag p24 is found beneath the matrix, and usually holds viral genetic material, 
consisting of two identical strands of RNA (Freed, 1998). 
The entire retroviral HIV genome, encoded by approximately 9-kb RNA, consists of nine 
genes flanked by long terminal repeat sequences (LTRs) (Frankel and Young, 1998) (Figure 
1.3). The genome consists of three classical retrovirus open reading frames (ORF) that 
encode the Gag (group-specific antigen), Pol (polymerase) and Env (envelope) polyproteins, 
which are then processed into individual proteins.  In addition to these three retroviral genes, 
the HIV-1 genome contains genes encoding for six regulatory or accessory proteins i.e. Nef, 
Rev, Vif, Tat, Vpu and Vpr. These accessory proteins are particularly important for viral 







Figure 1.3.Organization of the HIV-1 genome and virion (Frankel and Young, 1998) 
Figure 1.2. The structure of the HIV virion (Reproduced from (Lever, 2009)) 
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1.4.2 HIV GENE PRODUCTS 
1.4.2.1 GAG 
The gag gene encodes a Pr55
Gag
, a polyprotein precursor which is cleaved by the viral 
protease to produce four Gag proteins viz. matrix (MA or p17), capsid (CA or p24), 
nucleocapsid (NC or p7) and p6. The precursor protein, Pr55, is integrated into the budding 
virus, with cleavage occurring both during and after budding (Lever, 2009, Reicin et al., 
1996). The matrix protein, a 132 amino acid protein lining the inner surface of the virion 
membrane envelope, serves a primary function of targeting Gag and Gag-Pol polypeptides to 
the membrane preceding viral assembly. Furthermore, the p17 matrix protein is important for 
anchoring the gp41 transmembrane protein (TM). The p24 capsid is a 24 kDa structural 
protein that condenses to form the conical capsid core of the virus particle, which encloses 
the viral genomic RNA. The p9 nucleocapsid is a 55 amino acid protein, forming a coat 
around the RNA genome in the virus particle, delivering the RNA into the assembled virion. 
It is also involved in additional functions, including reverse transcription through improving 
the binding of the transfer RNA (tRNA) to the viral primer binding site(Frankel and Young, 
1998). Lastly, the p6, a 51 amino acid protein found at the C-terminal end of the Gag 
polyprotein, is known to enable budding of the virus from infected cells and further 
maturation of the viral progeny (Schubert et al., 2000). The p6 is also known to bind to the 
Vpr protein to incorporate it into the virus (Lever, 2009, Selig et al., 1999, Kondo and 
Gottlinger, 1996). 
1.4.2.2 POL 
The pol ORF encodes for the three viral enzymes, reverse transcriptase (RT), protease (PR) 
and integrase (IN)(Kaplan et al., 1994). The three Pol proteins need to come together as 
dimers (PR), heterodimers (RT) or tetramers (IN) to become functionally active in their 
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enzymatic activity. Initially, the Pol protein is formed as an extension of Gag by frame-
shifting to produce the Pr160 Gag-Pol fusion polyprotein, which is integrated in the virus 
particle. This polyprotein is cleaved to produce the various enzymatic components of the 
virus. The functions of the components include cleaving Gag proteins within the particle 
(protease) and inserting dsDNA into target cell chromosomes (integrase and reverse 
transcriptase) (Lever, 2009). PR is one of the prime targets for drug design, where some of 
the current drugs used in HIV-1 treatment target the active cleavage site of the protease 
enzyme to inhibit the activity of the protease enzymes and therefore prevent viral 
reproduction, thus resulting in a significant reduction in plasma viral load(Frankel and 
Young, 1998). 
1.4.2.3 ENV 
The envelope protein is a 160 kDa precursor glycoprotein (gp160), cleaved by cellular 
proteases, unlike Gag and Pol which are cleaved by viral proteases, to form the gp120 surface 
protein (SU) and the gp41 transmembrane protein (TM) (Tagliamonte et al., 2011).These 
proteins make up the outer membrane of envelope as well as the core of the virion, and are 
critical for HIV binding to their host cell receptors and are important for the ensuing cell 
entry. TM plays the role of an anchor of the envelope glycoprotein complex into the cell 
membrane and next into the virus envelope. SU, attached to TM by non-covalent bonds, 
bears the detection site for the cell surface receptor proteins by which HIV attaches to and 
enters the cell (Tagliamonte et al., 2011). The Env glycoprotein is able to evade antibody 
neutralization through its extremely variable amino acid sequences and glycosylation (Lever, 
2009). 
1.4.2.4 NEF 
HIV-1 Nef is a 206 amino acid myristoylated protein of 27-35 kDa in size that is produced in 
large quantities early in the HIV life cycle. It is one of the first viral proteins that is expressed 
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following infection and has been shown to act as an important virulence factor in HIV 
pathogenesis in vivo (Lever, 2009). Despite being initially identified as a 3' ORF that 
negatively influences viral replication thus termed "Negative factor", abbreviated to Nef, 
studies have shown that this protein actually acts as an HIV infectivity stimulant and leads to 
viral replication (Malim and Emerman, 2008, Chengmayer et al., 1989).The role of Nef as a 
critical determinant of pathogenicity has been established through observed evidence of long-
term survival in humans and rhesus macaques infected with HIV-1 or SIV (simian 
immunodeficiency virus) strains  respectively that lack intact nef genes (Deacon et al., 1995, 
Kirchhoff et al., 1995). The Nef protein has been shown to down-regulate the expression of 
CD4+, major histocompatibility complex (MHC) class I proteins and the interleukin-2 (IL2) 
receptor from the surface of infected cells (Lever, 2009). Thus, causing a disruption in the 
typical cell to cell interactions in immune responses. Nef in SIV causes a down-regulation of 
the T cell receptor on lymphocytes, therefore resulting in a reduction of cell activation. This 
process is absent in HIV Nef with the risk of activation-induced cell death being seen as an 
important pathogenic difference between the SIV and HIV (Lever, 2009). Further functions 
of Nef include the ability to alter cellular activation pathways and induce apoptosis and the 
ability to enhance virion infectivity.  
Lastly, Nef seemingly is involved in the recruitment of lymphocytes to infected macrophages, 
thus increasing spread of the virus. Importantly, the endocytosis of CD4+ T cells, the primary 
receptor of the virus from the surface of infected cells are accelerated in response to the Nef 
protein (Lever, 2009).   
1.4.2.5 VPU 
Vpu is another accessory protein employed by HIV-1 to reduce surface expression of the 
CD4 receptor on T cells. Vpu, a 16kDa, 81 amino acid long dimeric integral membrane 
protein acts similarly to Nef, greatly influencing dissemination, replication and persistence of 
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the virus. It is exclusively found in infected target cells and expressed ‘late’ in the viral life 
cycle. It augments virus export from the cell, reducing the formation of a complex of gp120 
being produced within the CD4 glycoprotein and the infected cell, essentially, assisting the 
virus escape the cell during budding by weakening the interaction of the new envelope 
proteins with cell receptors. In recent times it has been demonstrated that Vpu plays an 
important role in counteracting the inhibitory effects of tetherin, a cellular protein, on virus 
budding (Figure 1.4) (Lever, 2009, Malim and Emerman, 2008).   
1.4.2.6 TAT  
Tat is a 23-kDa regulatory protein of 86-101 amino acids in length, appropriately named for 
its primary function as a trans-activator of transcription from the HIV-1 long terminal repeat 
(LTR) promoter. It binds to the "Tat-responsive region" (TAR) in the newly transcribed virus 
mRNA. The binding process is initiated in order to form complexes with cellular 
transcription factors and together initiate transcription and elongation by RNA polymerase 
(Sodroski et al., 1985). This interaction greatly increases cellular RNA polymerase II activity, 
enhancing the generation of viral mRNA and essentially amplifying the amount of viral 
protein.    
1.4.2.7 VIF 
Vif is a 23-kDa accessory protein standing for 'viral infectivity factor'. Recent studies have 
shown that Vif interacts with and promotes the degradation of APOBEC-3G, which is a 
cellular cytidine deaminase that would usually attack viral genetic material (Figure 1.4). The 
human protein ABOBEC-3G and APOBEC-3F are loaded into virions in the absence of Vif, 
where they cause hypermutation of the HIV-1 genome following infection. Development of 
therapeutic interventions that restore the function of APOBEC could be an important 




Viral protein R (Vpr) is a 14 kDa size and 96 amino acid long accessory protein which has 
been shown to promote cell cycle arrest via a ubiquitin ligase mechanism and furthermore is 
thought to influence the expression of receptors for natural killer (NK) cells on infected cells. 
Vpr is involved in the process of transporting the "uncoated" virus to the host cell nucleus, 
following fusion and entry (Romani and Engelbrecht, 2009).  
Other primate lentiviruses, i.e. HIV-2 and simian immunodeficiency virus (SIV) possess an 
additional protein, Vpx (Puigdomenech et al., 2013). Vpx has been shown to aid in 
replication of HIV-2 and some SIV in myeloid cells, triggering the destruction of an early-
acting restriction factor and promoting synthesis of viral DNA in non-dividing cells. The 
restriction factor is SAMHD1, a deoxynucleoside triphosphohydrolase that cleaves 
deoxynucleotide triphosphates (dNTPs). SAMHD1 is not only active against HIV-2 and SIV 
but also HIV-1 that lacks Vpx. SAMHD1 has been demonstrated to negatively regulate virus-
induced immune responses in monocyte-derived dendritic cells (MDDCs), where silencing of 
SAMHD1 promoted HIV-1 recognition (Ryoo et al., 2014, Yang and Greene, 2014). 
SAMHD controls the sensitivity of MDDCs to HIV-1 infection during intracellular contact, 








1.4.2.9 REV  
Rev is a 19 kDa phosphoprotein of 118 amino acid length is a regulatory protein essential for 
HIV-1 gene expression and viral replication. Rev is primarily localized in the nucleus, 
serving the main function of transporting viral mRNA transcripts (partially spliced and 
unspliced) that encode genomic RNA and the structural proteins, Gag, Pol and Env, from the 
nucleus to the cytoplasm. Rev controls the switch from "early" to "late" stage of the lifecycle 
(Pollard and Malim, 1998).  
Figure 1.4. Vif, Vpu, and Vpr inhibit host cell restriction factors to promote efficient virus 
replication (Malim and Emerman, 2008) 
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1.4.3 HIV LIFE CYCLE 
 
Figure 1.5.The HIV viral life cycle. (Replicated from (Barre-Sinoussi et al., 2013)) 
 
Although HIV can infect various cells the main target is the CD4+ T lymphocyte (CD4+ T 
cell). Upon infection of the CD4+ T cell, the virus undergoes multiple steps to generate viral 
progeny viruses. The HIV life cycle is as follows: 
Binding and fusion  
The process of gp120 binding to CD4+ and the appropriate co-receptor (typically CCR5 or 
CXCR4), triggers a conformational change in the envelope proteins, exposing the 
hydrophobic region of the TM protein, allowing for insertion into the target membrane 
(Kwong et al., 1998). This aligns the virus envelope to the cell membrane, resulting in the 
virus fusing with the cell membrane. Once fusion occurs the virus gains access to the 




Uncoating and reverse transcription  
Once the HIV virion gets into the cell cytoplasm, the virus uncoats, releasing its 
nucleoprotein complex consisting of the matrix protein, reverse transcriptase, Vpr, integrase 
and the diploid viral genome (Miller et al., 1997). The reverse transcriptase (RT) enzyme 
reverse transcribes the viral RNA genomes into double stranded DNA, integrating the genetic 
material of the virus into the host DNA. 
Nuclear import and Integration  
The viral DNA and integrase are transported into the host cell nucleus after being assembled 
into the pre-integration complex (Figure 1.5), facilitated by Vpr and MA. The virus' new 
genetic material is then able to integrate itself into the host genome using the enzyme 
integrase, after which the viral DNA is referred to as 'provirus'. The provirus may stay 
inactive for extended periods or actively transcribe and then translate the genetic products for 
new viral replicates (Adams et al., 1994, Greene and Peterlin, 2002).  
Transcription/Replication  
When the host cell becomes activated, the virus uses its regulatory genes and various 
enzymes to create more genetic material and viral transcripts. Rev, tat and nef regulatory 
genes are expressed during the early stage of viral replication. Nef mRNA is particularly 
important, accounting for greater than 75% of all transcripts in newly infected cells. The gag, 
env and pol structural components are expressed as late gene products, requiring Tat for 
much more efficient transcription and Rev to transport unspliced mRNAs to the cytoplasm. 
Messenger RNA that has been suitably spliced does not require Rev, using the host cellular 




Assembly and Budding 
Upon targeting and binding by the Gag matrix protein, viral assembly occurs. The assembly 
of infectious vial particles begins with the incorporation of a coated p7 nucleocapsid complex 
which includes two RNA molecules. With this the virus buds from the cell, integrated the 
virion comprising of Envelope glycoproteins and structural Gag proteins, replicative enzymes 
and viral accessory proteins. Cyclophilin, a HIV-1 cellular protein is also incorporated into 
the virus, protecting it from post-entry inhibitory effects of Trim 5α, another cellular protein 
that prematurely disassembles the viral capsid (Greene and Peterlin, 2002).  
Viral maturation 
Essential in the generation of mature and infectious virions is the cleaving of Gag and Gag-
Pol precursors to form mature Gag and Pol proteins, which is assisted by the HIV protease 
enzyme which is activated during or after the virion has separated from the infected host-cell 
membrane (Kaplan et al., 1994).  
1.5 THE HOST IMMUNE RESPONSE TO HIV-1 INFECTION 
1.5.1 CLINICAL COURSE OF HIV-1 INFECTION 
The natural history of HIV is well documented. It comprises of an acute/primary phase that 
usually lasts a few months, followed by an early/clinically dormant phase that 
characteristically lasts for 3-10 years, and finally an immune collapse which is characterized 
by AIDS (Figure 1.6) (Pilcher et al., 2004). Acute HIV-1 infection is the interlude during 
which HIV is detectable in the blood serum and plasma, but before antibody formation, 
which is regularly used to diagnose infection (Schacker et al., 1996). HIV replication during 
the acute phase, usually results in high levels of viremia and shedding of the virus at mucosal 
sites. Onset of early virus-specific immune responses is coincident with a decrease in viremia 
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(Lavreys et al., 2000, Vanhems et al., 1999). Resting memory CD4+ T cells expressing 
CCR5 have been suggested to be the first cells infected in studies conducted in SIV infected 
rhesus macaques. The virus becomes detectable in local lymph nodes one week into 
infection, indicating an important role of Langerhan cells and plasmacytoid dendritic cells 
(pDCs) (Fonteneau et al., 2004). The virus is then able to attack the main target cell, i.e. 
CD4+ T cells, particularly HIV-specific CD4+ T cells in the draining lymph nodes (Douek et 
al., 2002). The virus spreads to various other sites after a week, with the gut-associated 
lymphoid tissue (GALT) being the most notable, with large numbers of CD4+CCR5+ 
memory T cells residing within. As a result, there is an exponential rise in infected cells, with 
up to 20% of gut-associated CD4+ T cells being infected and 80% destroyed, possibly by 
Fas-mediated bystander killing (Mattapallil et al., 2005). 
 
Even though there is strong evidence that the immune system is involved in the initial drop in 
viral load, more studies focused on elucidating the initial host-virus interactions are needed to 
allow deeper insights into HIV pathogenesis and disease progression (Speth et al., 2003, 
Yerly et al., 2001). Knowledge gained from such studies will inform vaccine design and 
improved therapies (Pope and Haase, 2003, McNeil et al., 2001, Oxenius et al., 2000). 
 
The acute period, is followed by a clinical latency phase, also known as the chronic stage. It 
is at this point that viral and host factors merge to dictate a virologic set point (Pantaleo and 
Fauci, 1996). Reaching the middle or end of this period, viral load begins to increase and 
CD4 count begins to decrease, which usually signals the progression of HIV symptomatic 
disease, leading to the eventual and full blown AIDS (Pantaleo and Fauci, 1996). However, 
according to Brenchley et al. (2006), chronic activation of the immune system is a better 
indicator of disease progression rather than plasma viral loads.  
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The course of infection is characteristically different for various individuals. Individuals can 
be sub-divided into (a) so-called "typical" progressors, (b) rapid progressors, (c) long-term 
non progressors (LTNP) and lastly (d) long-term survivors (Pantaleo and Fauci, 1996). A 
large number of individuals fall under the category of typical progressors, where following 
primary infection, these individuals experience an extended clinical latency period, with 
progression to clinically noticeable disease or an AIDS defining illness occurring within eight 
to ten years. This progression is quite varied amongst individuals and is dependent on 
numerous factors including CD4+T cell counts or other opportunistic infections. 
Approximately 10-15 % of HIV-infected individuals fall under the category of rapid 
progressors where they experience a rapid progression to AIDS within as little as two years 
of primary infection. The period of clinical latency may be lacking in rapid progressors, with 
the initial burst of viremia and subsequent rise in viremia remaining inefficiently controlled. 
Long-term non progressors constitute less than 5% of HIV infected individuals, where 
disease progression is not experienced for an extended period. Clinically, long-term non 
progressors are asymptomatic, with CD4+ T cell counts remaining stable and within the 
normal range. It remains unknown whether these individuals experience the same kind of 
primary infection as the other groups, with this information being important in understanding 
whether long-term non progressors are more swiftly and effectively able to control the initial 
burst and ensuing dissemination of the virus. Lastly, long-term survivors are those individuals 
that experience HIV disease progression within a comparable time frame to typical 
progressors, however both by clinical and laboratory examination, although atypical, they 
remain stable for an extended time period. These individuals are thought to possess either 
virologic or immunologic mechanisms to prevent further disease progression (Pantaleo and 









1.6 ANTIGEN PRESENTATION 
The human immune response system recognizes pathogens, acting to remove, immobilize or 
neutralize them. The adaptive immune system is antigen-specific, responding to specific 
molecules on a pathogen. Immunological specificity and memory involve recognition of a 
specific invader, repeated cell divisions resulting in large lymphocyte populations and 
differentiation into subpopulations of effector and memory cells (Goldrath and Bevan, 1999). 
Host lymphocytes are able to recognize self-proteins and therefore once non-self is detected 
the appropriate response is triggered. An antigen is an important non-self marker which 
triggers the formation of large lymphocyte populations. T cells acquire receptors for self-
Figure 1.6. Stages of HIV-1 infection as indicated by CD4 T-cell blood concentration 
(cells/mm
3
) and blood plasma HIV RNA (millions of copies/ml) (Reproduced from Online 







markers (MHC molecules) and for antigen-specific receptors upon initial differentiation and 
maturation and are thereafter released into the blood as naive T cells (Swain, 1983). These T 
cells ignore free-floating antigen and other cells that express MHC molecules. However, they 
will bind to antigen-presenting macrophages or other cell types. Antigen-presenting 
macrophages digest foreign cells, leaving the antigens intact. They then bind these antigens to 
MHC molecules on its cell membrane (Figure 1.7). These antigen-MHC complexes are 
recognized by certain lymphocytes, promoting repeated cell division and differentiation into 
effector and memory cells, all containing receptors for the antigen (Swain, 1983). Effector 
helper T cells secrete cytokines, stimulating T and B cells to divide and differentiate, while 
effector cytotoxic T cells recognize infected cells with the MHC-antigen complex (Gajewski 
et al., 1989, Glasebrook and Fitch, 1980). They then secrete perforins and other toxins in 
order to kill the infected cell. B cells receive an interleukin signal from the helper T cells 
which have been activated by a macrophage with the MHC-antigen complex, promoting 
rapid cell division, with effector B cells producing large amounts of free-floating antibodies. 
MHC molecules therefore play an important role in the process of antigen recognition and 
ultimate differentiation between self and non-self. 
 
Figure 1.7. Immune system recognition and response to pathogens/antigens (Reproduced  




1.6.1 MAJOR HISTOCOMPATABILITY COMPLEX (MHC) 
The major histocompatibility complex (MHC), referred to as human leukocyte antigen (HLA) 
in humans, was initially discovered as the genomic region responsible for determining 
compatibility between donor and recipient in tissue and organ grafts (Zinkernagel and 
Doherty, 1974). These experiments showed that cytotoxic T lymphocytes (CTLs) were able 
to recognize the MHC molecule, with further experiments by McMichael and colleagues 
elucidating that virus specific CTLs are able to recognize both the antigen and a polymorphic 
MHC molecule (McMichael et al., 1977). The MHC is a cluster of genes that maps to the 
short arm of chromosome 6. The most important of the genes spanning the four million base 
pairs of DNA and over 128 expressed genes, are the MHC Class I and Class II genes, which 
encode the “classical” antigen-presenting MHC molecules. These genes are vital in regulating 
immunity and recognition of antigenic foreign peptides (Carrington and O'Brien, 2003). 
Genes within the MHC complex encode for various other factors including cytokines, 
enzymes involved in intracellular antigen processing, heat shock proteins, as well as proteins 
with unknown function. B and T cells only recognize antigens “presented” to them bound to 
an MHC molecule. MHC class I presentation is often referred to as the cytosolic or 
endogenous pathway as MHC class I molecules present peptides derived from cytosolic 
proteins. Conversely, MHC class II molecules are derived from extracellular proteins and the 
MHC class II pathway of antigen presentation is often called the endocytic or exogenous 
pathway (Ploegh, 1998).  
In humans, this large group of genes is the most polymorphic loci in the entire human 
genome and is referred to as the Human Leukocyte Antigen (HLA). HLA gene products are 
central to acquired immune responses. The major HLA class I alleles can be divided into 
HLA-A, HLA-B and HLA-C, with the minor alleles including HLA-E, HLA-F, HLA-G and 
HLA-H. These are genetically inherited proteins that are present on the surface of every 
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nucleated cell of the body. The HLA class II genes, located within the HLA-D region, also on 
chromosome 6, include the gene products HLA-DR, DQ and DP (Campbell and Trowsdale, 
1993). 
Over 100 diseases have been shown to be associated with HLA loci, with the MHC complex 
shown to be an important genetic risk factor in infectious diseases as well as numerous 
autoimmune diseases and cancers, with HLA being linked to both susceptibility or resistance 
(den Uyl et al., 2004, Blackwell et al., 2009, Carrington and O'Brien, 2003, Borghans et al., 
2007). 
1.6.2 STRUCTURE OF MHC CLASS I MOLECULES 
The MHC class I molecules are heterodimers, comprising a heavy alpha 45 kDa glycoprotein 
and a light chain, beta-2-microglobulin (12kD) (Rigney et al., 1998). The alpha chain can be 
divided into three extracellular domains, ααand αin addition to the transmembrane 
region and cytoplasmic tail (Flutter and Gao, 2004, York and Rock, 1996). The class I 
molecule is expressed on the surface in association with β2 microglobulin, which is important 
for class I surface expression. The MHC-unique domains form the peptide-binding groove, 
which is formed by a β-pleated sheet structure and a sidewall consisting of two alpha-helices 
(αand α (Figure 1.8). The sequence polymorphism clustered in and around the peptide-
binding groove is the most distinctive feature between MHC class I molecules. The 
polymorphism modifies their biochemical properties, dictating binding specificities, and 
therefore different MHC class I alleles bind unique peptides (York and Rock, 1996). The 
peptide binding groove houses a short peptide of approximately 7 to 15 residues long, with 9-
11 residues peptides the most common, and the orientation of the bound amino acid residues 
always being the same. The N and C terminals are always positioned at respective ends, with 
the remaining residues, peptides associated with a particular MHC allele usually have 
conserved residues called 'anchors', housed in specialized small pockets found in the floor of 
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the groove (Klein and Sato, 2000). Polymorphisms in the peptide binding groove have a 
considerable effect on the peptide range associated with each MHC class I molecule, thus the 
interaction between MHC and peptide is known to be the most specific event in the antigen 
processing pathway (Gao et al., 2001). Peptide binding to the MHC class I molecule is 
essentially governed by anchor residues interacting with specific pockets.  
 
Figure 1.8. MHC Class I and MHC Class II structure. (Reproduced from Garland and 
Science, 2009). 
1.6.3 STRUCTURE OF MHC CLASS II MOLECULES 
MHC class II molecules comprise of two transmembrane glycoprotein chains of 34kDa and 
29 kDa. Each chain has two domains, α1 and α2, and β1 and β2 respectively. The β2 domain 
contains the CD4binding site. MHC class II molecules are similar to class I molecules in their 
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three-dimensional structure, with allelic differences also being due to polymorphisms within 
and around the peptide binding groove (Figure 1.8). The peptide binding grooves in class II 
molecules allow for the ends of peptides to actually extend along the groove, rather than 
being embedded in the molecule. With this, the peptide-binding groove can contain peptides 
that vary in length, typically between 13-17 amino acids (or even longer), however peptide 
length is not restricted in class II molecules. Definition of anchor residues and prediction of 
peptide binding motifs is difficult in class II molecules dues to its binding pockets being more 
accommodating of various amino acid side chains (Rudensky et al., 1991). 
1.6.4 ANTIGEN PRESENTATION PATHWAY OF MHC CLASS I and II 
 
 
Figure 1.9.MHC class I and class II antigen processing pathways. (Reproduced 
from(Neerincx et al., 2013)).  
MHC class I molecules present mainly endogenously processed peptides to CD8+ T cells. 
These peptides are derived from host proteins as well as intracellular pathogens and tumour 
specific antigens (Figure 1.9) (Yewdell et al., 2003). The immune system is then able to 
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monitor intracellular proteins for discrepancies, thus detecting viruses and bacteria concealed 
within the cell. Individuals cells can express up to six different MHC class I alleles, with each 
MHC molecule of a particular allele being able to potentially bind to billions of distinct 
peptides (York and Rock, 1996). The antigen processing and presentation pathway is what 
enables these extensive selection of peptides to load onto MHC molecule and present as 
peptide-MHC (pMHC) complexes on the cell surface.  
Conversely, MHC class II molecules present antigenic peptides that are derived from both 
endogenous and exogenous proteins to CD4+ T cells (Jensen, 2007). The peptides that are 
presented by MHC class II molecules are derived from self and foreign antigens that are 
internalized into phagosomes and endosomes through various mechanisms, which include 
macropinocytosis, phagocytosis and receptor-mediated endocytosis among others (Figure 
1.9). Class II molecules are only active in antigen-presenting cells (APCs), including B cells, 
macrophages, dendritic cells and thymic epithelial cells. Antigens are processed differently in 
each of these various cells; however the major components that are used are similar.  
1.7 ROLE OF IMMUNE MEDIATED CONTROL OF INFECTION 
The central function of the human immune system is to protect the host from invading 
pathogens and preserving the internal balance of the body. The internal world is referred to as 
self, with potential infectious agents from the external world recognised by the immune 
system as non-self. Some of the main functions of the immune system include: 
immunological recognition, generation of immune effector functions, immune regulation, 
immunological memory and limiting damage to self.  
The first lines of defence adopted by the immune system are physical barriers in the form of 
skin and mucosal barriers/cells lining the air passages and the gut. Any irregularities in these 
protective physical barriers would enable the entrance of foreign material into the body. Once 
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either bacteria or viruses penetrate the internal world, the immune system becomes activated. 
The activated immune system follows a sequence of events to finally destroy the pathogen. 
The bulk of the infectious agents that passes through the first line of defence are immediately 
dealt with by the second line of defence i.e. the innate immune system. The innate immune 
system is a natural, non-specific line of defence, consisting of cells that engulf whole 
particles or release toxic substances that may kill off these invading pathogens (Janeway, 
2001). These cells include natural killer (NK) cells, dendritic cells (DCs), macrophages, 
monocytes, neutrophils, basophils, T helper and B cells. The cells of the immune system 
recognise foreign objects through pattern recognition receptors (PRRs) which are found on 
the surfaces of micro-organisms bearing repeated patterns of molecular structures e.g. viruses' 
double stranded RNA. The invariant molecular structures called pathogen-associated 
molecular patterns (PAMPs) are produced only by the microbes and not host cells and are 
constitutive and conserved (Janeway, 2001). The innate immune system also includes 
intracytoplasmic proteins that bind to inactivate the pathogen- such as host restriction factors 
that bind HIV-1 proteins and restrict virus replication at various stages of the life cycle.  
If the pathogen is not destroyed by the innate immune system, the third line of defence i.e. the 
acquired or adaptive arm of the immune system is activated. Adaptive immunity is the 
response of antigen specific lymphocytes to antigen. Host defences are mediated by B and T 
cells following exposure to antigen, thus demonstrating specificity, diversity, memory and 
self/non-self recognition. Unlike the innate immune system which relies on a set of germ-line 
encoded receptors to recognize non-self, the adaptive immune system relies on somatically 
generated antigen receptors which are clonally distributed on T and B cells (Medzhitov and 
Janeway, 1998).  The adaptive immune system is based on clonal selection of lymphocytes 
and an activation of adaptive immune responses. 
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B cells synthesize a single type of antibody, proteins which recognize antigens as they 
develop and mature. Upon encountering specific antigens, B cells become primed for 
replication, consequent to receiving a signal from helper T cells, which are already activated 
by antigen-presenting macrophages. B cells differentiate into effector and memory B cells. 
Effector B cells produce antibodies which bind antigens and tag them for destruction by 
phagocytic cells and the complement system. B cells are unable to detect intracellular toxins 
or pathogens (Moir and Fauci, 2009). 
T cells are the second subset of lymphocytes that mediate the adaptive immune response. All 
T cells express CD3 on the surface along with the T cell receptor (TCR).  
CD8 which is expressed by subsets of CD3+ T cells make up a smaller proportion of CD3+ 
cells as compared to CD4 which is the major T cell subset in humans (CD4+ cells make up 
between 32-68 % of total lymphocytes). CD8+ T cells are involved in protecting the host 
from invading pathogens. These cells are referred to as cytotoxic T lymphocytes (CTL) and 
function by killing cells marked with foreign pathogens (Zhang and Bevan, 2011). 
CD4+ T cells, known as T 'helper' cells, ensure the efficient functioning of the adaptive 
immune system, shaping an effective response against pathogens. Diseases that destroy or 
impede CD4+ T cells e.g. HIV, causes immune dysfunction, eventually leading to 
degeneration (Soghoian and Streeck, 2010). 




1.8 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-SPECIFIC T CELL 
RESPONSES 
Strong cellular immune responses exhibited after HIV-1 infection have been shown to 
correlate with a decrease in viral load (Goulder and Watkins, 2004), however, the exact cell-
mediated in vivo mechanisms of virus control are poorly understood. HIV-specific T cell 
responses  play an important role in the decline of viral load during primary infection as well 
as in being able to influence viral load set point (Mellors et al., 1995, Mellors et al., 1996, 
Schacker et al., 1998). There has been evidence in humans showing that the appearance of 
HIV-specific CD8+ T cells coincides with a decrease in plasma viremia, during acute 
infection(Koup et al., 1994). Furthermore, the loss of HIV-specific CD8+ T cells has been 
associated with a swift progression to full blown AIDS (Klein et al., 1995). 
There have been several studies in both human and murine viral infections that indicate the 
generation of effective adaptive B and T cell antiviral effector responses are critically 
dependent on the presence of virus-specific CD4+ T helper cells (Homann et al., 2007, Norris 
and Rosenberg, 2002, Norris et al., 2004, Schacker et al., 1996). Despite this, one of the big 
gaps in HIV vaccine related research to date has been the relative neglect of the potential role 
of HIV-specific CD4+ T cell immunity in shaping effective adaptive antiviral immune 
responses (Ranasinghe et al., 2012).  
1.8.1 CD8+ T CELL RESPONSE TO HIV-1 INFECTION 
It is believed that CD8+ T cells play an important role in immune mediated control of HIV. 
Their main role is the recognition and killing of infected cells harbouring intracellular 
pathogens such as HIV. One of the key observations arguing for the role of CTLs in the 
initial control of virus replication is the temporal association between the emergence of CD8+ 
T cells and the rapid decrease in viral load during the acute phase of viral replication (Borrow 
et al., 1994, Koup et al., 1994, Schmitz et al., 1999). Additional studies have been able 
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demonstrate that CD8+ T cells have the ability to effectively inhibit viral replication ex vivo 
(Saez-Cirion et al., 2007). The most critical evidence for the role of CD8+ T cells in 
controlling HIV derives from the rhesus macaque model in SIV infection where depletion of 
CD8+ T cells using a monoclonal antibody resulted in a subsequent rise in SIV viral load and 
progression to disease (Jin et al., 1999, Metzner et al., 2000, Schmitz et al., 1999). Moreover, 
the detection of viral escape mutations in the CTL-targeted epitopes during early infection 
implies that CD8+ T cells mount a strong selective pressure on the virus (Allen et al., 2004). 
The progressive dysfunction and loss of HIV-specific CD8+ T cells have been implicated in 
increasing viral load and disease progression over time, together with the ongoing loss of 
CD4+ T cells. Other key attributes of CD8+ T cells, apart from the cytolytic activity 
previously mentioned, include polyfunctionality and functional avidity. The ability of CD8+ 
T cells to release a mixture of cytokines and chemokines in tandem have been shown to 
enhance cytolytic activity (Betts and Harari, 2008). Interestingly, polyfunctional CD8+ T 
cells have been shown to be elevated in a rare group of HIV positive individuals who 
maintain undetectable viral loads in the absence of any treatment, commonly referred to as 
elite controllers (Betts et al., 2006). 
Detailed characterization of the specificity of CD8+ T cell targeting of different HIV peptides 
have failed to correlate breadth and/or magnitude of HIV-1 specific CD8+ T cell responses 
with better control of viremia. Yet, these studies suggest that targeting of Gag is typically 
associated with immune control (Julg et al., 2010, Zuniga et al., 2006), with studies 
performed in clade C infection suggesting that broader targeting by Gag-specific CD8+ T 
cells is associated with lower viral load (Kiepiela et al., 2007, Maenetje et al., 2010, Riou et 
al., 2014). Collectively, however, findings from various laboratories highlight that CD8+ T 
cell activity is influenced by quality as opposed to quantity alone. 
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In addition, host genetic effects and MHC class I molecules have been widely studied, with 
strong association between the rate of disease progression and the HLA class I alleles being 
demonstrated. The expression of particular HLA class I alleles restricting HIV-specific CD8+ 
T cell responses are associated with different clinical outcomes. Various alleles such as HLA- 
B*57 or B*27 being labelled 'protective' alleles, whilst the accelerated onset of AIDS is 
associated with HLA-B*35. Overall, strong associations between HLA class I expression and 
viral control implicate an important role for HLA class I-restricted CD8+ T cells in the 
setting of HIV-1 infection (Carrington and O'Brien, 2003). 
Ultimately, HIV-specific CD8+ T cell responses are important in exerting an antiviral effect 
and in contributing to lowering viremia. However, although the role of CD8+ T cells has 
been widely studied in HIV-1 infection, very little is known about the role and contribution of 
CD4+ T cells to immune mediated control of HIV. 
1.8.2 CD4+ T CELL RESPONSE TO HIV INFECTION 
CD4+ T cells typically co-ordinate various processes of the adaptive immune system to 
ultimately shape an effective response against specific pathogens (Soghoian and Streeck, 
2010). However, CD4+ T cells are also known to be the primary targets of HIV-1 infection, 
acting as 'host' cells to aid in replication of the virus. As the number of functioning CD4+ T 
cells decrease, the weaker an individual's immune system becomes, making them more 
susceptible to various opportunistic infections and illnesses. The CD4+ T cell count is used as 
an important indicator of disease progression and survival of the individual. This value, 
which is measured as CD4 cells per cubic millimetre of blood, is used as a measure of when a 
person is put on antiretroviral treatment. The public sector in South Africa currently uses the 
count of ≤ 350 cells/mm
3
 as a guideline for treatment initiation, however are in the process of 
changing to the guidelines followed by the private sector and the international standard which 





During acute HIV-1 infection, there is an extensive depletion of memory CD4+ T cells from 
the lymphoid system, particularly in the gut through direct targeting of these cells as well as 
through bystander activation-induced cell death. Although studies have shown a preferential 
infection of HIV-specific CD4+ T cells over other antigen-specific CD4+ T cells (CMV) in 
the peripheral blood, the majority of antigen-responsive HIV-specific CD4+T cells remain 
virus-free at any time, even during peak viremia (Douek et al., 2002). 
The role of antigen-specific CD4+ T cells is controversial. Typically, CD8+ T cell responses 
are the dominant T cell responses in individuals infected with HIV-1, and this has been 
reflected in the study and volume of literature of HIV-specific CD8+ T cells. However, the 
maintenance of effector CD8+ T cell responses is critically dependent on CD4+ T helper 
cells (Janssen et al., 2003, Walker and McMichael, 2012).  
HIV-specific CD4+ T helper cells have been shown to be play an important role in generating 
long-lasting antiviral memory of CD8+ T cells (Sun and Bevan, 2003, Sun et al., 2004). 
While antigen-specific CD8+ T cells have the ability to be primed without CD4+ T cell 
assistance, subsequent expansion following the reencountering of the antigen is inefficient 
without CD4+ T cell help (Janssen et al., 2003, Matloubian et al., 1994, Williams et al., 
2006). The advanced loss of general CD4+ T cells and HIV-specific CD4+ T cells during 
HIV infection has been assumed to lead to the dysfunction of virus-specific CD8+ T cells and 
the unsuccessful suppression of these chronic viral infections (Day et al., 2006, Trautmann et 
al., 2006, Wherry and Ahmed, 2004). 
 
Yet, surprisingly very little attention has been given to the role of HIV-1 specific CD4+ T 
cells in controlling HIV infection. HIV-specific CD4+ T cells have been shown to have direct 
killing activity, both by in vitro cultured clones (Norris et al., 2004) and ex vivo (Soghoian et 
al., 2012). Nevertheless, the development and specificity of HIV-specific CD4+ T cell 
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responses in acute and chronic HIV infection, and relation to the development of broadly 
neutralizing antibody responses remain to be defined. The identification of the specificities 
and efficacies of these responses is likely to be vital for HIV vaccine design, since any 
protein based vaccines will most likely induce some degree of HIV-specific CD4+ T cells. 
Indeed, it will be important to identify which HIV-specific CD4+ T cells are induced in 
natural HIV infection in order to successfully augment the efficacy of these responses in 
future vaccines. Currently, only a small fraction of HIV-specific CD4+ T cell responses have 
been identified and specificities of the individual peptide responses have not been defined. 
This study addresses this lack of information, particularly in a clade C cohort in South Africa, 
which carries the highest burden of the HIV epidemic in world. 
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1.8.2.1 ASSOCIATION OF STRONG CD4+ T CELL RESPONSES DURING 
CHRONIC HIV-1 INFECTION WITH EFFICIENT VIRAL SUPPRESSION 
Recent studies have alluded to the role of HIV-specific CD4+ T cells in viral control in HIV-
1 infection. One of the first comprehensive studies to be conducted at the population level 
was carried out by Ranasinghe et al. (2012), where CD4+ T cell responses to individual HIV 
peptides were elucidated, generating an immunodominance profile of these responses. The 
presence and specificity of HIV-specific IFN- γ positive CD4+ T cell responses were 
evaluated in a large cohort in chronic clade B infection. The study demonstrated that the 
breadth of these CD4+ T cell responses was inversely correlated with viral load. Responses 
targeting Gag protein were most associated with favourable outcome. There were differences 
in the immunodominance profile of individuals that were able to control viral replication and 
those that were termed chronic progressors. Furthermore, the ratio between Gag and Env 
responses was a strong marker of viral control in the various groups, where increased Gag 
responses was associated with a lower viral load, and greater Env responses being linked to a 
higher viral load and an unfavourable clinical outcome (Ranasinghe et al., 2012). This study 
and others (Kaufmann et al., 2004, Ramduth et al., 2005, Ramduth et al., 2009) highlight the 
important role of HIV-specific CD4+ T cell responses in immune-mediated control of HIV-1 
infection. They also identified immunodominant CD4+ T cell epitopes that could potentially 
be included in future vaccines to augment protective T cell responses.  
 
Similar patterns of responses as seen in chronic clade B infection have been seen in chronic 
clade C infection. Ramduth et al. (2009), showed that IFN- γ secreting Gag-specific CD4+ T 
cell responses were immunodominant in chronic untreated HIV-1 infection. Here again the 
responses were directed at numerous distinct epitopes and associated with control of the 
virus. This evidence, particularly in clade C infection leads to the research detailed in this 
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thesis, where HIV-1 CD4+ T cell epitopes were further identified and characterized to 
provide detailed information on the important role of CD4+ T cells in viral control and more 
importantly to  highlight the need for clade specific vaccine development. Furthermore, 
although the Ramduth et al. (2009) study alluded to the impact of host genetic factors on 
HIV-1 specific CD4+ T cell responses in clade C HIV-1 infection; this was not examined in 
detail during their study. The research presented in this thesis aims to delineate the precise 
peptide-specificity and immunodominance of HIV-specific CD4+ T cell responses and 
investigate the presentation of these peptides by HLA class II molecules. 
1.8.2.2 CD4+ T CELL RESPONSES DURING ACUTE HIV-1 INFECTION 
The role of HIV-specific CD4+ T cells during acute infection has been less studied, with 
recent evidence by Schieffer et al., (2014) suggesting that the induction of HIV-specific 
CD4+ T cell responses during acute HIV infection does not fuel disease progression and is 
overall beneficial. Furthermore, longitudinal analysis showed that those epitopes targeted at 
high frequencies during acute infection were recognized at the same frequency by HIV-
specific CD4+ T cells during chronic infection. In addition, generation of Gag-specific CD4+ 
T cell responses during acute infection was shown to be inversely correlated with viral load 
set point in subsequent chronic HIV-1 infection (Schieffer et al., 2014). 
1.8.2.3 ASSOCIATION OF HLA-RESTRICTED CD4+ T CELL RESPONSES WITH 
HIV IMMUNE CONTROL 
Host genetic factors have a great influence on HIV disease progression (Carrington et al., 
2001, Cohen et al., 1997, Roger, 1998). These include genetic polymorphisms within the 
human leukocyte antigen (HLA) class I and class II loci (Gao et al., 2001, Pereyra et al., 
2010), chemokine receptors serving as HIV-1 co-receptors (O'Brien and Moore, 2000, 
Connor et al., 1997) and the genes that encode for the transporters associated with antigen 
processing (TAPs) (Malhotra et al., 2001, Abele and Tampé, 2004, York and Rock, 1996). 
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Currently virus-specific CD4+ T cell responses in HIV-1 infection are poorly defined and 
there is a lack of information on HLA class II restriction of HIV-specific responses. HLA 
class I alleles have been characterized, with their genetic association with HIV control being 
well defined (Gao et al., 2001, Pereyra et al., 2010). However, recent studies have suggested 
that HLA class II alleles may also have an effect on the control of HIV (Figure 1.10) (Julg et 
al., 2011, Malhotra et al., 2001, Ranasinghe et al., 2013). Several HLA class II DRB1*13 
alleles and the DRB1*13-DQB1*06 haplotype have been shown to bestow a degree of 
protection in terms of HIV disease outcome. Studies have shown that individuals expressing 
theses alleles, display the strongest HIV-specific CD4+ T cell responses (Ferre et al., 
2010)(Figure 1.10). The DRB1*1303 allele in particular has been associated with reduced 
viral loads in both subtype B and C populations (Julg et al., 2011, Ferre et al., 2010). The 
DRB1*13 allele has been shown to confer protection in other infections as well, particularly 
hepatitis B, where presence of this allele has been associated with a greater frequency of 
clearance as well as better clinical outcome (Julg et al., 2011). Although not conclusive, the 
finding of strong associations between class II HLA alleles and breadth and magnitude of 
CD4+ T cell responses re-iterates the important role that CD4+ T cells have in immune 
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1.9 ASSAYS TO DETERMINE EPITOPE SPECIFICITY AND FUNCTIONAL 
EFFICACY OF HIV-SPECIFIC CD4+ T CELLS 
The main assays used to measure HIV-specific CD4+ T cells include the interferon (IFN)-γ 
ELISPOT, tetramer-staining for common HLA-restricted epitopes and intracellular cytokine 
staining (ICS) measured by flow cytometry. Evaluating antigen-specific T cells and their 
effector functions is vital to understanding overall T cell immunity in terms of assessing the 
effectiveness  of specific immune therapies (Zhang et al., 2009). However, because of the low 
frequency at which these antigen-specific T cells occur in peripheral blood, consistent and 
reliable measurement of T cell immunity poses a major challenge.  
Table 1.1. Role of particular HLA alleles/ haplotypes on HIV-1 disease transmission, both 





The IFN- γ ELISPOT is based on the enzyme-linked immunosorbent assay (ELISA), where 
the main principle is detection of a cytokine (IFN- γ), through antigen induced secretion, 
which is bound by an immobilized antibody and later visualized using another enzyme-
coupled antibody (Czerkinsky et al., 1983). The ELISPOT assay was initially developed for 
detection of antibody-secreting B cells but is now widely used as a comprehensive screening 
method for HIV-specific CD8+ T- and CD4+ T cell quantification and characterization 
(Corne et al., 1999). Vaccine clinical trials in particular, utilize both ICS and IFN- γ 
ELISPOT as the main assays to assess vaccine immunogenicity (Streeck et al., 2009).  The 
ELISPOT is a rapid and cost-effective method used in the large scale detection and mapping 
of T cell responses. One of the limitations of the assay is that it works under the assumption 
that all HIV-specific CD8- or CD4+ T cells are identifiable by their ability to secrete IFN- γ 
post peptide stimulation. With this, some cells of interest may not be identified or the 
magnitude of particular responses may be skewed. In general, both ICS and the ELISPOT 
have not been able to show direct correlation with vaccine efficacy or protection in HIV-1 
infection however they are still able to provide useful functional information.  
There are various other assays that can be used to measure antigen-specific CD4+ T cells, 
both in number and function. However, each has pros and cons. One such assay is tetramer 
staining, a highly sensitive method used to screen for CD4+T cell responses to a pre-
determined peptide-HLA class II combination. However, tetramers are expensive and 
generation of class II tetramers is extremely difficult (both commercially and 'in-house'). 
Furthermore, the assay gives no functional information, it only measures the quantity of HIV-
specific T-cells to a given HLA-restricted epitope, although it can be combined in multi-
parameter flow cytometry with functional read-outs such as IFN-γ and other cytokines upon 
peptide stimulation (Sun et al., 2003).  
38 
 
For this study, we utilized overlapping peptides, spanning the entire HIV proteome, the 
ELISPOT megamatrix format. This approach is the most rapid, efficient and cost-effective 
method available to allow for a broader view of the overall immune response to HIV. We 
used ICS to further elucidate functional characteristics by measuring various other cytokines. 
1.10 SPECIFIC AIMS AND OBJECTIVES OF THE THESIS 
The precise details of CD4+ T cell contribution to immune protection against HIV have not 
been adequately defined, leaving a gap in the information needed for an effective vaccine 
design. My study focused on the role of CD4+ T helper cells in the immune response to clade 
C HIV infection.  
1.10.1 STUDY AIM 
The aim was to carry out a comprehensive analysis of HIV-specific CD4+ T cell responses to 
HIV-1 subtype C infection and to elucidate these responses in terms of class II HLA 
restriction. Furthermore, we evaluated functional qualities of CD4+ T cells restricted by 
protective class II alleles in a large cohort of individuals infected with HIV-1 subtype C 
infection in KwaZulu-Natal, South Africa. 
1.10.2 STUDY HYPOTHESIS 
We tested the hypothesis that HIV-1-specific CD4+ T cell responses restricted by class II 
HLA alleles play an important role in immune mediated control of HIV-1 infection.  
1.10.3 STUDY RATIONALE 
Our aim was to generate data that may elucidate the underlying mechanisms by which CD4+ 
T cells responses impact immune control of HIV. This information will be critical to vaccine 
efforts designed to induce these responses, as well as potential therapeutic manipulation of 
immunity in persons with acute and chronic clade C HIV-1 infection. 
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1.10.4 SPECIFIC OBJECTIVES 
Chapter 3 focuses on studies of  HIV-specific CD4+ T cell targeting during acute and chronic 
HIV-1 infection using the IFN-γ ELISPOT assay to define the immunodominance hierarchy 
of frequently targeted peptides in clade C infection. The chapter further evaluates the 
functional qualities of CD4+ T cells using flow cytometric analysis. These analyses were 
aimed at shedding light on the role of HIV-specific CD4+ T cell responses in HIV-1 subtype 
C infection. Chapter 4 defines the class II HLA restriction characteristics of HIV-specific 
CD4+ T cell responses. Defining HLA restriction and epitope specificity will provide a 
greater understanding of the association between protective class II HLA alleles and T cell 
immunity. This chapter provides information on allele frequency in the cohort and HLA class 
II associations in controllers and progressors. Finally, the overall implications and future 





























CHAPTER 2: METHODOLOGY 
2.1 STUDY POPULATION 
Samples from adult study participants of predominantly Zulu/Xhosa ethnic origin with both 
acute and chronic infection were recruited from the Sinikithemba Clinic based as McCord 
Hospital (chronic infection) and Prince Mshiyeni Hospital (acute infection) in the greater 
Durban area of KwaZulu-Natal, South Africa. The study was approved by the Biomedical 
Research Ethics Committee (BREC) of the University of KwaZulu-Natal (BE190.13). All 
study participants provided written informed consent for participation in the study. All 
subjects were informed of their CD4+ T cell count and plasma viral loads. Subjects meeting 
the South African national criteria for treatment were referred for antiretroviral therapy, with 
only therapy-naive subjects being included in this study. 
2.1.1 ACUTE SAMPLING STRATEGY AND PATIENT SELECTION 
A total of 15 acute HIV-infected subjects were analysed in this study. Study participants 
testing negative or discordant by dual commercial rapid HIV-1 tests (Bioline, Standard 
Diagnostics; and Sensa, Hitech Healthcare) were initially recruited from HIV Counselling 
and Testing centers. Acute HIV-1 infection was defined by a positive HIV-1 RNA test, 
negative HIV-1 enzyme immunoassay (SD HIV1/2 enzyme-linked immunosorbent assay 
[ELISA] 3.0, Standard Diagnostics), and a negative or indeterminate Western blot (Genetic 
Systems, Bio-Rad). Centers for Disease Control and Prevention (CDC) criteria were used for 
the interpretation of Western blot results such that a positive sample had at least 2 of the 
major bands (gp160, gp120, gp41 and p24),with either gp160 or gp120 present as well as 
gp41 or p24. An indeterminate result was one in which these requirements were not met but 1 
or more bands were present, or where the band intensity was less than the weak positive 
control. Negative results exhibited no reactive bands. The infection date was estimated as 
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occurring 14 days prior to the first positive HIV RNA and negative HIV antibody test. Blood 
samples were obtained from study participants at 2, 4, 6, 8, 12, 18, 26 and 52 weeks post-
infection.   
2.1.2 CHRONIC SAMPLING STRATEGY AND PATIENT SELECTION 
A total of 55 chronically HIV-infected subjects were analysed in this study. Study 
participants comprised of antiretroviral naive, chronically HIV-1 subtype C–infected adults 
from the Sinikithemba cohort. Socio-demographic characteristics, plasma viral load 
measurements, and CD4 cell counts were obtained at baseline. Follow-up CD4+ T cell counts 
and plasma viral load measurements were performed at 3- and 6-month intervals, 
respectively.  
2.2 VIRAL LOAD DETERMINATION, CD4+ T-CELL ENUMERATION AND HLA 
TYPING 
Plasma HIV-1 RNA levels were quantified using the Roche Amplicor version 1.5 on the 
Roche Cobas Amplicor instrument according to manufacturer's instructions (Roche 
Diagnostics, Branchburg, NJ).The lower limit of detection of the assay was 50 RNA 
copies/ml plasma.  
Absolute blood CD4+ T-cell counts were enumerated using the MultiTest TruCount kit and 
MultiSet software on a FACS Calibur flow cytometer (Becton Dickinson). 
Genomic DNA samples were typed to an oligoalleleic level using Dynal RELITM reverse 
sequence-specific oligonucleotide (SSO) kits for the HLA-A, HLA-B and HLA-C loci (Dynal 
Biotech). Refining the genotype to the allele level was performed using Dynal Biotech 
sequence specific priming (SSP) kits in conjunction with the previous SSO type. Sequence 
specific oligonucleotide probes were immobilized on a membrane strip. Classical HLA class 
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II and I alleles were identified by the banding patterns produced by the selective 
hybridization of the sample amplicon to the probes on each locus specific strip. 
It should be noted that all viral load assays and CD4+ T-cell enumeration were performed by 
in house laboratories. While the HLA typing was performed by a collaborator, Carrington 
Lab, Center for Cancer Research at National Institute of Health, Frederick, Maryland, USA. 
2.3 SEPARATION AND CRYOPRESERVATION OF PERIPHERAL BLOOD 
MONONUCLEAR CELLS (PBMCs) 
2.3.1 SEPARATION OF PBMC 
2.3.1.1 PRINCIPLE 
The Ficoll density gradient method was used for the isolation of PBMCs from whole blood 
samples by our in house laboratories. Whole blood was overlaid onto Ficoll-Histopaque 1077 
(Sigma) and centrifuged in a Sorvall RT7 Plus centrifuge (Thermo Scientific). During 
centrifugation, those cells with greater density such as erythrocytes and granulocytes are 
trapped in the lower layer of the tube. Mononuclear cells migrate, forming a distinct opaque 
layer at the plasma/histopaque interface. 
2.3.1.2 PROCEDURE 
Histopaque 1077 (Sigma), Phosphate Buffered Saline (PBS) containing antibodies and R10 
medium  (RPMI 1640 containing 10% heat-inactivated fetal calf serum, 2 mM l-glutamine, 
50 U of penicillin/ml, 50μg of streptomycin/ml, and 10mM HEPES) were brought to room 
temperature. Whole bloods obtained from patients were initially centrifuged at 1,500 rpm for 
10 minutes. After spinning, 10 ml of plasma was removed and stored in 15 ml Sterilin tubes 
for viral load testing. 
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A 1:1 dilution of blood to PBS was then made, which was then gently layered over the 
Histopaque 1077 in a 1:1:1 dilution in a 50 ml Sterilin tube. The diluted blood, forming a 
layer above the Histopaque was centrifuged at 1,500 rpm for 30 minutes at room temperature. 
Following centrifugation, the opaque layer containing the mononuclear cells was aspirated 
and transferred to a second 50 ml Sterilin tube. 40 ml of PBS was added to the tube, which 
was then centrifuged for at 1,500 rpm for 10 minutes at room temperature. The supernatant 
was discarded and an additional 40 ml of PBS was added to the tube for a second wash at the 
same speed and duration. Once again the supernatant was discarded, with the pellet gently re-
suspended and warm R10 media added to the tube. The sample was incubated at 37º C in a 
5% CO2 incubator, counted, with the necessary amount of cells being used in various 
immunological assays if need be or cryopreserved if not utilized immediately.   
2.3.2 CRYOPRESERVATION OF PBMCs 
PBMCs for cryopreservation were centrifuged at 1,500 rpm for 10 minutes at 4º C. The 
supernatant was discarded, the pellet gently re-suspended and the tube thereafter transferred 
into an ice box. Each cryovial contained 10 million cells (which were prior determined using 
either a Guava Cell Counter or haemocytometer). If freezing 10 million cells, 500µl of fetal 
calf serum (FCS) was added to the cells and thoroughly mixed. An additional 500µl of FCS 
and 20% dimethyl sulfoxide (DMSO) was then added into the tube in a drop-wise manner 
bringing the total DMSO concentration to 10%. The cells in the freezing solution were then 
transferred to cryovials, which were stored in freezing containers (Mr. Frosty's - Nalgene) 
overnight at -80º C. Mr. Frosty's contain iso-propanol which cool at a rate of 1º C per minute, 
which is considered optimal for cell quality. Cells were moved from Mr. Frosty's after 24 
hours and placed in liquid nitrogen for long-term storage.  
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2.3.3 THAWING OF CRYOPRESERVED PBMCs 
Cryopreserved cells were removed from liquid nitrogen and rapidly thawed at 37º C in a 
water bath, until ice just began to become liquid. The cells were then re-suspended in 1ml 
cold R10 medium and transferred to Sterilin tube containing 9ml of cold R10 medium. The 
tube was centrifuged at 1,800 rpm for 6 minutes at 4º C. The supernatant was discarded, 
ensuring maximum removal of media containing DMSO freezing solution, due to toxicity of 
the chemical to cells once thawed. A second wash containing 10ml R10 medium was 
conducted at the same speed and duration as initially. The cells were thereafter re-suspended 
in 10ml cold MACS buffer solution prior to counting and CD8+ T cell depletion or 10ml R10 
medium if cells were not to be depleted.  
2.4 CD8+ T CELL DEPELETION USING MACS MICROBEADS 
Post cold thawing procedure, PBMCs were CD8+ T cell depleted using Miltenyi MACS 
MicroBeads. A buffer solution i.e. a 0.5% BSA/PBS solution was freshly prepared and stored 
on ice or at 4º C prior to usage. Once cells were thawed and washed twice in R10 medium, 
they were re-suspended in 10ml cold buffer solution and centrifuged at 1,800rpm for 6 
minutes at 4º C. 10µl of cell solution was added to 90µl of trypan blue at this stage and 
transferred to a haemocytometer for counting. After centrifugation, the supernatant was 
discarded and cells were re-suspended in 80µl of buffer solution and 20 µl of MACS 
MicroBeads. The cells were then incubated for 15 minutes at 4º C.  
During the incubation period a Miltenyi MACS magnetic stand was set up, together with LS 
magnetic columns to be used in the separation. The column was wet using 1ml of buffer 
solution prior to adding the cells. Post incubation, 500µl of buffer was added to the cell 
solution. Cell solution was then passed through the LS column. The flow-through was 
collected and passed through the column again. 3ml of buffer solution was added to the 
original tube containing the cells, washing the tube for any remaining cells and thereafter 
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passing the solution through the column. Lastly, once all previous solution has passed 
through, 3ml of buffer solution was passed directly through the column. The flow-through 
(approximately 7ml of solution) was thereafter centrifuged at 1,800rpm for 6 minutes. The 
supernatant was discarded and the cells i.e. whole PBMC minus CD8+ T cells was re-
suspended in 10 ml R10 medium and incubated at 37º C for resting until usage.  
Flow cytometry confirmed at least 98% CD8-negative PBMC prior to use in the IFN-γ 
ELISPOT assay. 
2.5 IFN-γ ELISPOT ASSAY 
2.5.1 SYNTHETIC PEPTIDES AND PEPTIDE MATRICES 
The IFN-γ ELIPOT assay was used to screen samples from all of the acutely and chronically 
infected subjects prior to conducting other immunological assays. The initial screening was 
carried out using a megamatrix of peptides. These peptides were produced at the 
Massachusetts General Hospital Core facility in 2001. The megamatrix involved the use of 
four hundred and ten 18-mer peptides overlapping by 10 amino acids that spanned the entire 
expressed HIV proteome. These were arranged into 72 pools of between 10 to 12 peptides in 
each pool such that an individual peptide was uniquely represented in two different pools. 
The peptides listed in tables 3-5 were used to set up the matrix, which has been designed to 
identify T-cell responses. The peptides in row A and B, C and D and E and F work in tandem. 
An example could be that if there was a T-cell response in row A, there would be one in row 
B as the particular OLP that the patient is responding to is present in both rows. By looking at 
table 1, the OLP can be identified. A particular example being a response to OLP 11, which 
will result in spot forming units in well A1 and B11(Note that peptides 108,109,110 and 132-
144 do not exist in the clade C list).  
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Positive responses from initial megamatrix screening were confirmed using a separate 
ELISPOT assay at single peptide level as described in section 2.5.2.  
Table 2.1. Positioning of OLP used in the megamatrix in rows A and B of 96 well ELISPOT 
plate 
 
Pool  A OLPs  
No of 
Peptides  




A1 1-11 11 B1 1 13 25 37 49 61 73 85 97 121 x x 10 
A2 12-22 11 B2 2 14 26 38 50 62 74 86 98 122 x x 10 
A3 23-33 11 B3 3 15 27 39 51 63 75 87 99 111 123 x 11 
A4 34-44 11 B4 4 16 28 40 52 64 76 88 100 123 124 x 11 
A5 45-55 11 B5 5 17 29 41 53 65 77 89 101 113 125 x 11 
A6 56-66 11 B6 6 18 30 42 54 66 78 90 102 114 126 x 11 
A7 67-77 11 B7 7 19 31 43 55 67 79 91 103 115 127 x 11 
A8 78-88 11 B8 8 20 32 44 56 68 80 92 104 116 128 x 11 
A9 89-99 11 B9 9 21 33 45 57 69 81 93 105 117 129 x 11 
A10 100-107 8 B10 10 22 34 46 58 70 82 94 106 118 130 x 11 
A11 111-121 11 B11 11 23 35 47 59 71 83 95 107 119 131 x 11 























Pool  OLPs  
No.  
Peptides  




C1 145-156 12 D1 145 157 169 181 193 205 217 229 241 253 265 277 12 
C2 157-168 12 D2 146 158 170 182 194 206 218 230 242 254 266 278 12 
C3 169-180 12 D3 147 159 171 183 195 207 219 231 243 255 267 279 12 
C4 181-192 12 D4 148 160 172 184 196 208 220 232 244 256 268 280 12 
C5 193-204 12 D5 149 161 173 185 197 209 221 233 245 257 269 281 12 
C6 205-216 12 D6 150 162 174 186 198 210 222 234 246 258 270 282 12 
C7 217-228 12 D7 151 163 175 187 199 211 223 235 247 259 271 283 12 
C8 229-240 12 D8 152 164 176 188 200 212 224 236 248 260 272 284 12 
C9 241-252 12 D9 153 165 177 189 201 213 225 237 249 261 273 285 12 
C10 253-264 12 D10 154 166 178 190 202 214 226 238 250 262 274 286 12 
C11 265-276 12 D11 155 167 179 191 203 215 227 239 251 263 275 287 12 
C12 277-288 12 D12 156 168 180 192 204 216 228 240 252 264 276 288 12 
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Table 2.3. Positioning of OLP used in the megamatrix in rows E and F of 96 well ELISPOT 
plate 
Pool OLPs  
No. 
Peptides  




E1 289-300 12 F1 289 301 313 325 337 349 361 373 385 397 409 421 12 
E2 301-312 12 F2 290 302 314 326 338 350 362 374 386 398 410 422 12 
E3 313-324 12 F3 291 303 315 327 339 351 363 375 387 399 411 423 12 
E4 325-336 12 F4 292 304 316 328 340 352 364 376 388 400 412 424 12 
E5 337-348 12 F5 293 305 317 329 341 353 365 377 389 401 413 425 12 
E6 349-359 11 F6 294 306 318 330 342 354 366 378 390 402 414  11 
E7 360-370 11 F7 295 307 319 331 343 355 367 379 391 403 415  11 
E8 371-381 11 F8 296 308 320 332 344 356 368 380 392 404 416  11 
E9 382-392 11 F9 297 309 321 333 345 357 369 381 393 405 417  11 
E10 393-403 11 F10 298 310 322 334 346 358 370 382 394 406 418  11 
E11 404-414 11 F11 299 311 323 335 347 359 371 383 395 407 419  11 













2.5.2 ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY 
HIV-specific CD4+ responses were screened against 410overlapping-peptides (OLPs) 
spanning the entire HIV-1 clade C consensus proteome at the level of a single peptide per 
well in a modified IFN-γ enzyme-linked immunospot (ELISPOT) assay. CD8-depleted 
PBMC, were plated in 96-well polyvinylidene plates (MAIP S45, Millipore, MA, USA)pre-
coated with 100µl MAb1-D1k anti-IFN-γ monoclonal antibody (0.5µg/ml) (Mabtech, 
Stockholm, Sweden) overnight at 4ºC. Prior to adding CD8-depleted cells the plate was 
washed 6 times with blocking buffer (PBS with 10% sterile heat inactivated fetal calf serum) 
to block non-specific binding sites. 90µl of R10 medium was added to each well. Thereafter 
10 µl of a 33 µg/ml peptide stock solution (overlapping peptides) was added to each well, 
acting as a stimulus. The final concentration of each peptide used was 2µg/ml, with a single 
OLP tested per well. 
A total of 100,000 CD8-depleted cells per well were added to each well in the presence or 
absence of specific stimulus, in this case HIV-1 derived OLPs in a final volume of 200 µl 
R10. Negative controls consisted of 4 wells of cells in medium without antigen or other 
stimuli. The addition of phytohemagglutinin antigen (PHA) (Sigma), at a concentration of 
5µg/ml, served as a positive control for both cell viability and functionality of the 
immunoassay. The plates were incubated for 40 hours at 37°C, 5% CO2 to elicit the maximal 
cytokine secretion.  
Following the 40-hour incubation the plates were processed as follows. Cells were discarded 
and the plate washed with 100 µl PBS per well 6 times. Thereafter, 100µl biotinylated anti-
IFN-γ MAb 7-B6-1 (0.5 µg/ml, Mabtech) detection antibody was added to each well. The 
plates were incubated for 90 minutes in the dark, at room temperature.  
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The plate was then washed 6 times again with 100 µl PBS per well. Thereafter, 100 µl 
streptavidin-alkaline phosphatase conjugate (0.5 µg/ml, Mabtech) enzyme was added to each 
well. The preparation of the aforementioned detection antibody and conjugate enzyme was 
prepared by adding 5 µl of antibody to 10ml of commercial PBS. The plate was incubated for 
45 minutes in the dark at room temperature.  
Lastly, the plate was once again washed for 6 times with 100µl of PBS per well. A 
combination of BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) and NBT 
(Nitro-Blue Tetrazolium Chloride), where 100 µl of each NBT and BCIP was added to 10ml 
of Tris buffer and 100 µl of this solution was added to each well. This solution is ideal for 
staining applications as they yield an intense, insoluble black-purple precipitate. The plate 
was closely watched for the appearance of spots, with the reaction being stopped by washing 
the plate under running water before discoloration appeared in the negative well.  
The AID ELISpot Reader (Autoimmun Diagnostika, Germany) was used to determine the 
spot-forming cells (SFC) per million CD8-depleted PBMC. The number of antigen-specific 
CD4+ T cells was calculated by subtracting the mean negative control values. An antigen-
specific CD4+ T cell response was considered positive only if it was at least >3 times the 
mean background and also >3 times the standard deviation of the SFC within the negative 
controls, as per Ranasinghe et al. (2012). The breadth of responses is defined as the sum of 
IFN-γ-positive peptide responses within a given individual across the entire HIV proteome or 
within a specified protein. 
2.6 HIV-SPECIFIC CD4+ T CELL LINES 
 
Frozen CD8-depleted peripheral blood mononuclear cell (PBMC) samples from subjects with 
known CD4+ T cell responses was used to generate CD4+ T cell lines.  CD8-depleted PBMC 
was simulated with 10 ug/mL of peptide at a concentration of 2 million cells on a 24-well 
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plate in H10 medium (RPMI 1640 containing 10% heat inactivated fetal calf serum, 2 mM L-
glutamine, 50µg of penicillin/ml, 50 µg of streptomycin/mL, and 10 mM HEPES).  The cells 
were incubated at 37°C and 5% CO2.  After 2 days, the cells were washed and fresh H10 
medium supplemented with 100 U/mL recombinant interleukin-2 (IL-2) was added.  The 
CD4+ T cell lines were fed twice weekly with regular media exchanges. 
2.7 HLA-DR RESTRICTION ASSAY 
 
After 14 days, the T cell lines were simultaneously assessed for their specificity and HLA-
DR restriction using a large panel of L cell line (LCL) mouse fibroblasts, each stably 
transfected with a single HLA-DR molecule, as previously described (Southwood et al., 
1998).  Each LCL was  pulsed with 10 µg/mL peptide for 90 minutes at 37°C and 5% CO2 
and washed five times to remove free peptide. Clade C consensus sequence HIV overlapping 
peptides were used in the assay. 10,000 peptide-pulsed LCL was co-cultured in triplicate with 
50,000 of each respective CD4+ T cell line per well on a pre-coated IFN-γ plate.  As a 
negative control, each CD4+ T cell line was co-cultured in triplicate with the appropriate 
LCL in the absence of peptide.  As a positive control, PHA was added at 2µg/mL. The plates 
were incubated overnight at 37°C and 5% CO2 and processed as per usual ELISPOT protocol 
described above. The AID ELISPOT reader was used to determine the number of spot-
forming cells (SFC) per 50,000 of the CD4+ T cell line. HLA-DR restriction was considered 
positive if it was at least ≥3 times the mean background and also ≥3 times the standard 




Figure 2.1. Graphical depiction of a typical response to co-culturing of T cell and L cell lines 
in a HLA-DR restriction assay (Ranasinghe et al., 2013). 
2.8 INTRACELLULAR CYTOKINE STAINING 
Intracellular cytokine staining is a flow cytometric technique used to detect single cell 
expression of cytokines, allowing for simultaneous detection, quantification and phenotypic 
characterization of antigen-specific CD4+ and CD8+ T cells in PBMC. 
Post thawing of cells and a minimum two-hour resting period, cells were plated at a volume 
of 100µl per well (i.e. having the desired number of cells in 100µl). Peptide pools were used 
as specific antigen/stimulus; with 10µl being added at a concentration of 2µg/ml. 
PMA/Ionomycin was used as positive control with 10µl being added at a concentration of 
2µg/ml. The stimulated cells were incubated at 37°C and 5% CO2 for one hour. Following 
incubation Golgi stop protein transport inhibitor (BD Biosciences) (0.25µl) and Golgi plug 
protein transport inhibitor (BD Biosciences) (0.25µl) was added to each well. The plate was 
then incubated overnight at 37°C and 5% CO2. Following incubation the cells were spun 
down at 2000rpm for 6 minutes. The supernatant was discarded and cells were washed with 
200 µl PBS and centrifuged at the same speed. Live/dead fixable aqua dead cell viability dye 
(Invitrogen) was thereafter added to each well (1:5 dilution with PBS). Cells were incubated 
with 40 µl per well viability dye in the dark for 10 minutes. The cells were washed with 200 
µl PBS and centrifuged at 2,000rpm for 6 minutes. The supernatant was discarded and a 
53 
 
surface stain (surface antibodies) was added to the cells and incubated in the dark for 20 
minutes. The cells were washed in a 2% FCS/PBS solution after incubation and spun down at 
2,000rpm for 6 minutes. Cytoperm/cytofix fixation permabilisation kit (BD Biosciences) was 
added to each well to fix the cells and incubated for 15 minutes. The cells were thereafter 
washed with perm wash (200 µl) and centrifuged at 2,000rpm for 8 minutes. Lastly, the 
intracellular staining antibodies were added to each well and incubated for 30 minutes. Post 
incubation, the cells were washed with 2% FCS/PBS solution and spun down at 2,000rpm for 
8 minutes. The supernatant was discarded, cells were re-suspended in 300 µl 2% FCS/PBS 
and transferred to cluster tubes to be analysed by the LSRII flow cytometer (Becton 
Dickinson). A minimum range of 100,000 – 200,000 events were acquired. Flow data was 
analysed using FlowJo software (Treestar FlowJo version 9.5.2). 
Table 2.4. Flow cytometry panel indicating antigens and fluorochromes used in functional 
analysis 
 
2.9 STATISTICAL ANALYSIS 
Statistical analysis and graphical presentation were performed using GraphPad Prism version 
5.0 software. Spearman’s Rank correlation was used to assess the relationship between 
immune responses and viral load.  Statistical analysis of significance was calculated using 
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one-way ANOVA with Dunn’s test for multiple comparisons. Statistical significance was set 
at p < 0.05.  
CHAPTER 3: DEFININGIMMUNODOMINANCE HIERACHIES OF HIV-SPECIFIC 
CD4+ T CELL RESPONSES IN SUBTYPE C HIV-1 INFECTION 
3.1 BACKGROUND 
A hallmark of HIV-1 infection is the loss of CD4+ T cells. In particular, HIV-1-specific 
memory CD4+ T cells are preferentially susceptible to infection and are gradually depleted 
from the periphery and GALT (Douek et al., 2002). Studies in chronic infections, in both 
animal models and humans, have demonstrated that CD4+ T cells are required for optimal 
CD8+ T cell responses (Mattapallil et al., 2005, Janssen et al., 2003). However, the 
contribution of HIV-specificCD4+ T cell responses to viral control is unclear, particularly the 
relationship between HIV-specific T helper cell function and HIV-1 subtype C infection. 
Several studies have shown that HIV-specific CD4+ T cells play an important role in 
enhancing immunological control of HIV viremia by either providing help to CD8+ T and B 
cells or having direct antiviral effects (Chevalier et al., 2011, Norris et al., 2004, Soghoian 
and Streeck, 2010). Furthermore, studies have illustrated that there is a greater presence of 
HIV-specific CD4+ T cells in individuals that are able to spontaneously control viral 
replication without antiretroviral therapy (Zhang and Bevan, 2011, Rosenberg et al., 1997). 
Our current understanding of CD4+ T cell immunology in the setting of HIV-1 infection is 
skewed towards studies conducted mainly in subtype B infection, which is the predominant 
subtype in North America and Europe. However, in sub-Saharan Africa, which carries the 
highest burden of the epidemic, clade C virus is the predominant subtype. Our study provides 
additional insight to a previous study conducted on CD4+ T cell responses in subtype C 
infection by Ramduth et al. (2009). This study aims to identify HIV-specific CD4+ T cell 
responses to HIV subtype C infection at single epitope level. The identification of HIV-1 
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CD4+ T cell epitopes and a thorough understanding of the relationship between these 
responses and control of viremia is critical in designing a vaccine that could elicit CD4+ T 
cell responses protective against subtype C HIV-1 infection.  
The first objective was addressed by the following goals: 
(i)  Evaluate the immunodominant regions of the HIV-1 proteome targeted by HIV-specific 
CD4+ T cells during the first year of acute HIV-1 infection and determine how these 
responses evolve over time. 
(ii) Define the individual peptide sequences that are targeted by HIV-specific CD4+T cell 
responses in chronic HIV-1 infection. Here, overlapping peptide pools that span every 
encoded HIV protein was used, allowing for a broader view of the overall immune response 














3.2.1 ACUTE HIV-1 INFECTION 
 
Table 3.1. Clinical characteristics of acutely infected HIV-1 subtype C-infected adults. 
 
Our acute infection cohort consisted of 15 individuals divided into various groups according 
to viral load. Controllers were those individuals that were able to spontaneously control viral 
replication below a level of 2000 HIV RNA copies/ml in the absence of any antiretroviral 
therapy. Progressors were those individuals that indicated varying levels of viral replication 
and progression to clinically noticeable disease. The groups were further divided as seen in 
Table 3.1 above. All individuals were of Zulu/Xhosa ethnicity between the ages of 25 - 33 






Subcohort definition (viral load) 
No. of  
subjects 
Median viral  
load 
(copies/ml)  
Median CD4 cell  




Gender %  
(female) 





Elite controller (EC) 0 — — — — — — 
<50 copies/ml  
Viremic controller (VC) 1 1125 571 0 100 100 33 
51-2,000 copies/ml  
Low-viremic progressor (LVP) 2 4757 690 0 100 100 25 
2,001-10,000 copies/ml (4,363-5,150) (605-774) 
Intermediate-viremic progressor (IVP) 6 32718 622 50 50 100 29.5 
10,001-50,000 copies/ml (10,513-44,721) (343-790) (16-58) 
High-viremic progressor (HVP) 6 153607 356 33 67 100 26.5 




3.2.1.1 Gag and Pol regions of the HIV proteome most frequently targeted in acute 
HIV-1 infection. 
In order to assess the relative contributions of CD4+ T-cell responses to different viral 
proteins, we investigated the ability of peptide pools representing expressed gene products to 
induce IFN-γ production inCD8-depleted PBMC. We screened a total of 15 acutely HIV-
infected subjects using the IFN-γ ELISPOT megamatrix assay with synthetic peptides 
spanning HIV-1 Gag, Pol, Env, Nef, Tat, Vpr, Rev, Vif, and Vpu regions. The magnitudes 
(strength of responses) of HIV-specific CD4+ T cell responses ranged from 3 to 1998 
SFU/million (Figure 3.1). Interestingly, all subjects had detectable HIV-specific CD4+ T cell 
responses (15/15), and the vast majority of patients made a response to more than one protein 
(14/15, 93%) (Figure 3.1). Importantly, all subjects had strong Gag- and Pol specific T-cell 
responses, with these proteins contributing to 69% of the total responses made by all 
individuals, with Gag responses totalling 36% and Pol 33% (Figure 3.2). In contrast, Nef and 
Env were infrequently targeted, with only 10 and 9 % of responses, and very few responses 
were detected against HIV accessory proteins (Figure 3.2). These data suggest that the 
immunodominance of HIV-specific CD4+ T cell responses in acute clade C infection are 
biased towards Gag and Pol, which are highly conserved regions of the HIV proteome.  
The role of HIV-specific CD4+ T cell responses and influence on disease outcome during 
acute infection has not been well characterized. However, our study was in agreement with 
recent work by Schieffer et al. (2014), which also showed an immunodominance of Gag-
specific CD4+ T cell responses during acute clade B infection in a combined Berlin and 
Boston cohort. Unfortunately we could not determine CD4+ T cell responses at the single 
peptide level for acute infection due to limitations in sample availability; however the 
screening data represented in Figure 3.1 demonstrate the induction of robustCD4+ T cell 
responses targeting Gag during acute HIV-1 infection. 
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Figure 3.2. (A) Average CD4+ T cell response targeting of all subjects to various viral proteins 






3.2.1.2 CD4+ T cell targeting across the proteome remains stable over time (range of 1 -
23% variation between time points). 
In order to assess the evolution of CD4+ T cell responses over time, longitudinal analysis of 
CD4+ T cell responses in our acute cohort of 15 subjects was performed, with three separate 
time points assessed for 12 subjects and two time points analysed for 3 subjects (Figure 3.3). 
The average protein dominance of HIV-specific CD4+ T cell responses remained stable over 
time, with Gag-specific responses detected at an average magnitude of 249 SFC/mil, 387 
SFC/mil and 402 SFC/mil over the 1-2, 3-11 and 12-36 months respectively. Proteins 
targeted at high frequencies as early as 4 weeks post infection were recognized at similar 
frequencies 1 year and even 3 years post infection, suggesting that CD4+ T cell responses 
continually target the same region of the virus. These data are consistent with observations by 
(Schieffer et al., 2014). 
Interestingly, although the dynamics of HIV-specific CD8+ T cell responses are fairly well 
characterized very little is known about the evolution of HIV-specific CD4+ T cell responses. 
While it has been reported that Nef is the most targeted protein by HIV-specific CD8+ T cells 
in acute infection (Radebe et al., 2014), our study found that Gag and Pol were the most 







3.2.1.3 Gag/Pol specific CD4+ T cell responses and their impact on viremia. 
Having demonstrated in Figure 3.1-3.3 that Gag and Pol were the most dominant regions of 
the proteome targeted, we next wanted to analyse whether these responses had an impact on 
viral load set point. The average viral load between 3 and 12 months post infection was the 
measure of viral load set point used in this study. Figure 3.4 highlights a significant positive 
correlation between the total magnitude of CD4+ T cell responses (multiple time points) and 
viral load set point. Importantly, we found that the magnitude of Gag and Pol-specific CD4+ 
T cell responses (combined) was significantly associated with viral load set point (p=0.006, 
r
2
= 0.85). These data suggest the greater the magnitude of Gag/Pol specific response, the 
higher the viral load set point. The higher viral load set point would indicate faster 
progression to disease, suggesting a potentially detrimental effect of the induction of 
Gag/Pol-specific CD4+ T cell responses in acute infection. This could be because HIV-
Figure 3.3. Average CD4+ T cell response targeting  various viral proteins over a period of   
1-36 months post infection (range of time points assessed across all individuals) (n=15). 
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specific CD4+ T cell responses are preferentially targeted by HIV infection as reported 
previously (Douek et al., 2002).  
Intriguingly, analysis of Gag and Pol individually, rather than combined showed no 
significant association with viral load set point for Gag responses (albeit close to 
significance; p= 0.08, Figure 3.5A). However, a significant positive correlation was detected 
for Pol-specific responses with viral load (p= 0.0013, Figure 3.5B), indicative that the 
association with high viral load set point was driven by the Pol protein. There was no 
association of Env-specific CD4+ T cell responses and clinical outcome (Figure 3.5C). It has 
been previously demonstrated that individuals that have higher Env-specific responses at 
baseline would initiate HAART significantly earlier than those individuals that had higher 
Gag-specific responses (Schieffer et al., 2014).  
These results need to be interpreted with caution as the analysis of HIV-specific CD4+ T cell 
responses were conducted using pooled peptides. Results need to be confirmed in 





p = 0.006 
R2= 0.85 
Figure 3.4. Relationship between magnitude of Gag/Pol specific responses and viral load 
set point (n=9), showing results for individuals where initial time of infection could be 
















Figure 3.5. Relationship between magnitude of individual Gag (A), Pol (B) and Env (C) specific 
responses and viral load set point (n=9 for Gag and Pol-specific responses, and n=6 for Env-
specific responses), showing results for individuals where initial time of infection could be 
identified. CD4+ T cell responses were measured across various time points (ranging from 1-36 







3.2.2 CHRONIC HIV-1 INFECTION 
Table 3.2. Clinical characteristics of chronically infected HIV-1 subtype C-infected adults. 
 
Our chronic infection cohort consisted of 55 individuals divided into various groups 
according to viral load. As with the acute infection cohort, controllers were those individuals 
that were able to spontaneously control viral replication below a level of 2000 HIV RNA 
copies/ml in the absence of any antiretroviral therapy. Progressors were those individuals that 
indicated varying levels of viral replication and progression to clinically noticeable disease. 
The groups were further divided as seen in Table 3.2 above. Majority of the individuals were 
of Zulu/Xhosa ethnicity between the ages of 38 - 44 years old. The cohort consisted of 




Subcohort definition (viral load) 
No. of  
subjects 
Median viral load   
(copies/ml) (range) 
Median CD4 cell  
count (cells/µl)  
(range) 
Race (%  
Black) 




Elite controller (EC) 3 41 582 33 67 100 44 
<50 copies/ml  (20-50) (340-699) (43-55) 
Viremic controller (VC) 12 1136.5 646.5 8 92 100 43 
51-2,000 copies/ml (235-2,000) (210-1,100) (32-68) 
Low-viremic progressor (LVP) 11 6130 513 9 91 100 38 
2,001-10,000 copies/ml (2,100-9600) (225-676) (31-42) 
Intermediate-viremic progressor (IVP) 16 24300 365 38 63 94 43 
10,001-50,000 copies/ml (11,933-49,000) (217-773) (35-59) 
High-viremic progressor (HVP) 16 202000 383.5 13 88 94 41 





3.2.2.1 Screening of CD4+ T cell targeting across entire HIV-1 proteome in chronic 
infection. 
To better understand the role of HIV-specific CD4+ T cell responses, we next investigated 
the presence and specificity of these responses in the setting of chronic clade C HIV-1 
infection.  For this analysis, we utilized a cohort of 55 chronically HIV-infected individuals 
(that was separate from the acute cohort). In the chronic cohort, HIV-specific CD4+ T cell 
responses were screened against a panel of 410 pooled peptides (megamatrix) spanning the 
entire HIV-1 clade C consensus sequence using the IFN-γ ELISPOT assay. Initial screening 
was conducted using pooled peptides due to limitations with sample availability. Results 
illustrate a representation of all proteins in all subjects tested, with Gag being the most 
dominant region targeted (100%, 31/31) (Figure 3.6).Pol was the second most dominant 
protein targeted, similar to what we observed in acute infection (Figure 3.7) Strikingly, all 
patients demonstrated more than one detectable HIV-specific CD4+ T cell responses.  

































Figure 3.6. Megamatrix screening data indicating n=31 responders, subdivided into CD4+ T 











































3.2.2.2 No significant relationship between the breadth and magnitude of HIV-specific 
CD4+ T cell responses and disease outcome i.e. viral load and CD4 count 
 
We next evaluated the relationship between HIV-specific CD4+ T cells and to two well 
defined markers of HIV disease progression viz. viral load and absolute CD4 counts (Mellors 
et al., 1997). Peptides identified in the megamatrix screening were tested at single peptide 
level, assessing the presence and specificity of HIV-specific IFN-γ CD4+ T cell responses in 
a cohort of 31 chronically infected individuals (subjects not exhibiting a response in the 
megamatrix screening were not tested with single OLPs). Peptide sequences that induce HIV-
specific T cell responses in chronic HIV-1 infection were identified.  
Figure 3.7. Megamatrix screening data indicating hierarchy CD4+ T cell responses per HIV-1 
viral protein (n=31 responders). 
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The breadth (number of responses) and magnitude (strength of responses) of overall HIV-
specific CD4+ T cell responses did not correlate with contemporaneous viral load (Figure 
3.8). Given the immunodominance of Gag responses, we examined whether Gag-specific 
CD4+ T cell responses impacted viral load and found no significant correlation. However, 
here too no significant correlation was observed between breadth and magnitude of Gag-
specific responses and contemporaneous viral load (Figure 3.9). These data are contrary to 
what has been reported in other studies such as (Ramduth et al., 2009, Ranasinghe et al., 
2012). Previous data suggested an inverse correlation between the total breadth of HIV-
specific CD4+ T cell responses and viral load (Ranasinghe et al., 2012). Furthermore, the 
magnitude of responses to Gag also showed a strong inverse correlation with viral load 
(Ranasinghe et al., 2012). A possible explanation for our results could be our small sample 
number, where as we only studied 20 subjects, Ramduth et al. studied 373 subjects and 
Ranasinghe et al. studied 93 subjects. Other possible explanations for the difference could be 
the methods used, where Ramduth et al. used ICS to screen for Gag-specific IFN-γ CD4+ T 
cell responses. 
Out of the 55 subjects tested in our chronic infection cohort, 35 individuals showed no HIV-
specific CD4+ T cell response. We therefore investigated if there was a difference in the level 
of persistent viremia between individuals with detectable CD4+ T cell responses to those 
with no detectable responses. We examined the relationship between contemporaneous viral 
load and total CD4+ T cell responses (Figure 3.10 A) as well as Gag-specific responses 
(Figure 3.10 B) between the groups. There was no significant difference observed between 
both total response and Gag-specific response to contemporaneous viral load in these 
subjects. Once again, a limitation of these results is the sample size available for analysis.  
In our chronic infection cohort we had 15 controllers and 40 progressors. We therefore 
investigated if durable CD4+ T cell responses were associated with prolonged virus 
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suppression. We evaluated the CD4+ count and breadth of total responses between the 
groups. Consistent with previous reports (Mellors et al., 1997), controllers had a significantly 
higher (p = 0.01) CD4 count as compared to progressors (Figure 3.11). However, no 
significant difference between the breadth of total responses was observed between 
controllers and progressors (Figure 3.12).  
Overall, results from our chronic infection cohort illustrate that Gag-specific CD4+ T cell 
responses are the most dominant; similar to what is observed in the acute infection cohort. 
Furthermore, no significant relationship between the breadth and magnitude of HIV-specific 
CD4+ T cell responses and disease outcome (viral load) was observed. Further investigation 











































R= - 0.08  
 
p = 0.57 
R= - 0.13  
 
 
Figure 3.8. Characterization of the relationship between breadth (A) and magnitude (B) of 
HIV-specific CD4+ T cell responses to contemporaneous viral load (n=20). Spearman’s 






































Figure 3.9. Characterization of the relationship between breadth (A) and magnitude (B) of Gag-
specific CD4+ T cell responses to contemporaneous viral load (n=16). Spearman’s rank correlation 
































Figure 3.10. (A) Comparison of differences in viral load between responders (n=20) and non-
responders (n=35). (B) Comparison of differences in viral load between Gag responders (n=16) 


















Figure 3.11. Comparison of differences in CD4 count between controllers (n=15) and 
progressors (n= 40). Two-tailed t-test was utilised for statistical analysis. 
Figure 3.12. Comparison of differences in breadth of CD4+ T cell responses between 




3.2.2.3 Immunodominance hierarchy of CD4+ T cell responses in chronic infection. 
We next characterized epitope specificity of HIV-specific CD4+ T cell responses to 
individual peptides. Results from confirmatory IFN-γ ELISPOT assays identifying peptides 
at single peptide level were used to define the HIV-specific CD4+ T cell epitope targeting in 
chronic clade C HIV infection. HIV-specific CD4+ T cell responses in chronic clade C 
infection dominantly target the Gag region (Figure 3.12). The most dominantly targeted 
region in Gag was within the p24 protein (15/40 peptides). This region of Gag has also been 
shown to be immunodominant for HIV-specific CD8+ T cell responses and has been 
previously been associated with viral control (Streeck et al. 2007). The dual dominant 
targeting by CD8+ and CD4+ T cells could have a possible role in enhancing viral control. 
Our data showed that OLP-41 is the most dominantly targeted peptide making up 15% of all 
the measured responses in our cohort (Table 3.1). The second most commonly targeted 
epitope was within OLP 37 (9%) and the third was OLP 40 making up 9% of all detectable 
responses (Table 3.1). The p17 (9/40) region of Gag was the next most dominantly targeted 
region. Additional immunodominant epitopes were located within the Gag p15 (5/40) and 
Nef region of the protein (7/40 peptides) (Table 3.1). The results highlight a large number of 
detectable HIV-specific CD4+ T cell responses across the HIV proteome, dominantly 
targeting Gag and Nef (Figure 3.13).  Concordant with what has been  previously reported in, 
chronic, untreated clade C HIV-1 infection, IFN-γ – secreting Gag-specific CD4+ T cell 
responses are immunodominant and are directed at multiple distinct epitopes(Ramduth et al., 
2009). Surprisingly, epitopes in the envelope region were rarely targeted in clade C infection 
as compared to multiple epitope targeting in this region in clade B (Ranasinghe et al., 2012). 
Further analysis into the lack of response targeting this part of the proteome needs to be 
conducted. One possible explanation for the paucity of detectable Env responses could be 
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because we used frozen PBMCs for our analysis, with the highly conserved responses being 

































peptide Protein Peptide OLP Sequence 
 
15 p24 41 YVDRFFKTLRAEQATQDV 
9 p24 37 WIILGLNKIVRMYSPVSI 
9 p24 40 GPKEPFRDYVDRFFKTLR 
7 p17 6 ASRELERFALNPGLL 
7 p24 22 WVKVIEEKAFSPEVIPMF 
7 p24 25 GATPQDLNTMLNTVGGH 
4 p17 2 RGGKLDKWEKIRLRPGGK 
4 p17 4 GKKHYMLKHLVWASREL 
4 p17 5 KHLVWASRELERFAL 
4 p17 7 ERFALNPGLLETSEGCK 
4 p17 14 IEVRDTKEALDKIEEEQNK 
4 p24 46 TILRALGPGASLEEMMTA 
4 Nef 81 KKRQEILDLWVYHTQGYF 
2 p17 11 TGTEELRSLYNTVATLY 
2 p17 12 SLYNTVATLYCVHAGIEV 
2 p17 13 LYCVHAGIEVRDTKEAL 
2 p17 16 NKSQQKTQQKAAADKGKV 
2 p24 18 GKVSQNYPIVQNLQGQMV 
2 p24 21 PRTLNAWVKVIEEKAF 
2 p24 30 LHPVHAGPIAPGQMREPR 
2 p24 32 MREPRGSDIAGTTSTL 
2 p24 38 IVRMYSPVSILDIKQGPK 
2 p24 39 SILDIKQGPKEPFRDYV 
2 p24 42 LRAEQATQDVKNWMTDTL 
2 p24 44 MTDTLLVQNANPDCKTIL 
2 p24 45 NANPDCKTILRALGPGA 
2 p15 48 ACQGVGGPSHKARVLAEA 
2 p15 57 WKCGKEGHQMKDCTERQA 
2 p15 58 QMKDCTERQANFLGKIW 
2 p15 62 FLQSRPEPTAPPAESFRF 
2 p15 63 TAPPAESFRFEETTPAPK 
2 Nef 67 MGGKWSKCSIVGWPAIR 
2 Nef 76 EVGFPVRPQVPLRPMTFK 
2 Nef 77 QVPLRPMTFKGAFDLSFF 
2 Nef 78 FKGAFDLSFFLKEKGGL 
2 Nef 80 GLEGLIYSKKRQEILDLW 
2 Nef 82 LWVYHTQGYFPDWQNY 
2 RT 168 GMDGPKVKQWPLTEEKIK 
2 Integrase 252 GYIEAEVIPAETGQETAY 
2 Vpr 272 IWKGPAKLLWKGEGAVVI 
 
Table 3.3. Most frequently targeted peptides in clade C infection (% targeting of specific  






















Figure 3.13. Percentage frequency targeting of HIV-specific CD4+ T cell responses to 
overlapping peptides across the HIV-1 proteome. 
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3.3 FUNCTIONAL QUALITIES OF CD4+ T CELLS IN CHRONIC SUBTYPE C 
INFECTION 
3.3.1 BACKGROUND 
Th cells play important roles in coordinating adaptive immune responses. They carry out 
functions principally through the secretion of cytokines and chemokines that activate and/or 
recruit target cells (Zhu and Paul, 2008). The four CD4 T cell subsets mediate various 
responses within an individual. Th1 cells are known to mediate immune responses against 
intracellular pathogens. Th2 cells promote host defence against extracellular parasites. Th17 
cells mediate immune responses against extracellular bacteria and fungi. Lastly, Treg cells 
are critical in the maintenance of self-tolerance and in regulation of immune responses 
(Figure 3.14) (Zhu and Paul, 2008) .  
More recently CD4+ T-follicular helper cells (Tfh) have been established as a distinct CD4 T 
cell type, shown to be essential for B cell help in vivo, highlighting the importance of these 
cells for protective immunity (Crotty, 2011). Tfh cells are essential for the development of 
antigen-specific B cells within germinal centres (GC). Tfh cells through the interaction of co-
stimulatory receptors, provide important soluble factors (i.e. IL-4, IL-21) to promote survival, 
isotype switching and selection of high affinity memory B cells and plasma cells (Crotty, 
2011). One of the major challenges surrounding Tfh cells is understanding the dynamics 
between Tfh cells in the lymph nodes as compared to those in the periphery, described as 
“peripheral Tfh”. Studies by Boswell et al., (2014) have demonstrated that while sharing 
some characteristics with Tfh cells, peripheral Tfh cells may not embody a good substitute in 
studying T- and B cell dynamics within lymphoid tissue. All things considered, the 
relationship between CD4 T cells and B cells during HIV infection, specifically with relation 
to the generation of broadly neutralizing antibodies remains a key consideration in the study 







Here, in this study, we focus on the cytokines secreted by HIV-specific CD4 T cells to better 
understand their potential contribution to HIV-1 control through direct antiviral activity or 
'helper' functions. We looked at the following cytokines in particular: 
IFN-γ: one of the principal secretions of Th1 cells. IFN-γ is important in the activation of 
macrophages, increasing their microbicidal activity. IFNγ is also known to play an important 
role in the activation of cytotoxic T cells to destroy virally infected cells. Furthermore, IFNγ 
induces further production and secretion of IL-2 in activated APCs, thus strengthening the 
Th1 response and suppressing any Th2 response (Moir and Fauci, 2009, Suzuki et al., 1988). 
Figure 3.14. Summary of the four CD4+ T cell subsets; indicating functions, unique products, 
characteristic transcription factors and important cytokines responsible for their fate 
determination. Reproduced from (Zhu and Paul, 2008). 
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IL-2: production of IL-2 is important for CD4 T cell memory. In addition, IFN-γ, IL-2 
secreting cells are considered as the precursors of Th1 memory cells (Zhu and Paul, 2008, 
Darrah et al., 2007).  
TNF-α: one of the greatly studied pro-inflammatory cytokines because of the key role it plays 
in the origin and progression of HIV-1(Bahia and Silakari, 2010).  
IL-17: has the ability to induce many inflammatory cytokines. Furthermore, IL-17 recruits 
and activates neutrophils during host immune response to extracellular bacteria and fungi 
(Korn et al., 2007, Zhou et al., 2007).  
IL-13: has been shown together with IFN-γ to be associated with viral suppression and a lack 
of HIV-1 disease progression when secreted by activated T cells (Bailer et al., 1999) 
IL-21: is a stimulatory factor for Th17 differentiation, also acting on CD8 T cells, B cells, 
NK cells and dendritic cells (Korn et al., 2007, Veldhoen et al., 2008, Zhou et al., 2007). 
Having provided examples of cytokines studied in this thesis, it is important to remember that 
the balance between different functions of a single cytokine, or between the synergistic and 
antagonistic actions of different cytokines, determines the ultimate effect of cytokine changes 
in an HIV infected person.  
The second objective was then to: 








Having elucidated IFN-γ responses to various regions of the HIV-1 proteome using the 
ELISPOT assay, we wanted to further assess the effector functions of HIV-specific CD4+ T 
cell responses to HIV-1 infection using intracellular cytokine staining. We evaluated 
functional qualities of CD4+ T cells of 25 HIV-1 chronically infected individuals for whom 
we had available samples using flow cytometric analysis. Peptide pools of the Gag, Nef and 
Env region of the proteome were analysed. This analysis enables a more accurate 
quantification of antigen-specific T cells. 
Figure 3.15 illustrates a HIV-specific CD4+ T cell IFN-γ andTNFα response to Gag pool 
stimulation.  
IFN-γ (Figure 3.16), IL-2 (Figure 3.17) and TNFα (Figure 3.18) were the most frequently 
secreted cytokines whereby 18 out of 25 individuals studied secreted at least one of these 
cytokines. Most of these responses were induced upon Gag stimulation. As shown in Figure 
3.16, Gag stimulations induced moreIFN-γ compared to Env (p <0.01). Significant 
differences were also observed in TNFα secretion between all stimulations (Gag, p <0.001, 
Gag- Nef, p <0.01 and Gag-Env, p < 0.01). However, there was no difference in responses 
for IL-2 production across different HIV proteins.  
Collectively, these data confirm that Gag is the most immunodominant protein targeted by 
HIV-specific CD4+ T cells during the chronic stage of infection. Moreover, these data go 
beyond previous work on untreated clade C infection (Ramduth et al., 2009) to demonstrate 
the ability of Gag-specific CD4+ T cell responses to secrete multiple Th1 cytokines. These 
additional functional data allows for a better understanding of the role of HIV-specific CD4+ 
T cells in the setting of HIV-1 infection. Further work is now ongoing to assess whether 
specific cytokines are linked with immune control of clade C infection. Previous literature in 
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clade B infection has suggested that polyfunctional secretion (specifically IFN-γ+ and IL-2+) 
by HIV-specific CD4+ T cells is enhanced in elite controllers, although this is arguably a 

















Figure 3.15. Gating strategy and graphical representation indicating a HIV-specific CD4+ T cell 
response to Gag pool stimulation. 
Lymphocytes Singlets CD3 CD4/CD8 
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Figure 3.16. Functional response indicating IFN-γ secretion of HIV-specific CD4+ T cell 
responses to pooled peptides across the three regions of the HIV-1 proteome (n=18). One-way 
ANOVA was utilised for statistical analysis. 
Figure 3.17. Functional response indicating IL-2 secretion of HIV-specific CD4+ T cell 


















































Figure 3.18. Functional response indicating TNFα secretion of HIV-specific CD4+ T cell 
responses to pooled peptides across the three regions of the HIV-1 proteome (n=18). One-way 





CHAPTER 4: HLA CLASS II RESTRICTION CHARACTERISTICS OF HIV-
SPECIFIC CD4+ T CELL RESPONSES IN CHRONIC SUBTYPE C INFECTION 
 
4.1 BACKGROUND 
Having described the vital role that CD4+ T cells play in adaptive immunity during acute and 
chronic HIV-1 infection, we next studied the role of host genetics in the setting of HIV-1 
infection. There is strong evidence of an association between CD8+ T cells restricted by HLA 
class I alleles and HIV disease outcome, with particular alleles being identified for their role 
in conferring protection or rapid progression to AIDS (Kiepiela et al., 2004, Carrington and 
O'Brien, 2003, Gao et al., 2001). HLA class II molecules present antigens to CD4+ T cells, 
with their role being considered central to the development and maintenance of HIV-specific 
CD4+ T helper cells (Julg et al., 2011). Despite knowledge of the potential role of HLA class 
II alleles in HIV-1 infection, there have been only a few studies that have identified a few 
class II alleles associated with slower HIV disease progression (Chen et al., 1997, Malhotra et 
al., 2001, Ferre et al., 2010, Ndung'u et al., 2005, Ranasinghe et al., 2013).  Most studies have 
focused on specially selected patient subsets e.g. long-term non progressors. However, the 
role of HLA class II alleles in chronic progressive HIV infection, particularly in clade C 
infection is lesser studied and for the most part remains unknown.  
The influential role of genetic effects on disease progression will allow for greater insight 
into HIV pathogenesis. Furthermore, analysis of clade B CD4+T cell epitopes binding to 
HLA class II molecules has revealed a high degree of promiscuity amongst the epitopes 
(Ranasinghe et al., 2013). This property may be beneficial in vaccine design, with these 
epitopes being able to induce responses amongst a wide array of HLA Class II types.  
The HLA-DRB1 restriction assay utilized in these experiments has not been previously used 
to test restriction in clade C infection. The method was adopted from Ranasinghe et al. 
85 
 
(2013). In brief, frozen CD8-depleted PBMCs were used to grow 102 HIV-specific CD4+ T 
cell lines recognizing a wide range of peptide specificities from 27 HIV-infected individuals, 
with known CD4+ T cell responses and tested in functional HLA-DRB1 restriction assays. 
The T cell lines were successfully expanded and simultaneously assessed for their specificity 
to a particular peptide and HLA-DRB1 restriction using a panel of mouse L cell line 
fibroblasts stably transfected with a plasmid encoding a single recombinant human HLA-
DRB1 allele. The HLA class II typing of individuals were previously elucidated and therefore 
restriction was tested against an L cell line stably transfected with a matching HLA-DRB1 
variant.  
The third objective was as follows: 
(i) Define the class II HLA restriction characteristics and epitope specificity of HIV-specific 
CD4+ T cell responses using the HLA-DRB1 restriction assay. 
4.2 RESULTS 
4.2.1 HLA-DRB1 13:01 most frequent allele among CD4+ T cell responders. 
 
In order to perform HLA-DRB1 restriction studies, we first determined allele frequencies at 
the DRB1 locus in CD4+ T cell responders from our  chronic infection cohort (n=20). 
DRB1*13:01 was the most common allele observed (n=7, 22% of responders) followed by 
DRB1*03:02 (n = 4, 13% of responders) (Figure 4.1). Our data suggests that individuals with 
the strongest HIV-specific CD4+ T cell responses possessed class II HLA-DRB1*13 alleles. 
Of the 20 responders, 34% had one of three HLA-DRB1*13 alleles i.e. HLA-DRB1*13:01, 
HLA-DRB1*13:02, or HLA-DRB1*13:03 (Figure 4.1). These results concur with what has 
been found in other studies of HLA class II frequencies in clade C HIV infection, where 
DRB1*13:01 and DRB1*03:02 were also seen at the highest frequencies (Ndung'u et al., 
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2005). The DRB1*13 alleles has been reported to confer a protective effect (Ferre et al., 
2010, Chen et al., 1997), as well as certain haplotypes of this allele being associated with an 











































































































4.2.2 HLA-DRB1 allele restriction characteristics of HIV-specific CD4+ T cell responses 
in subtype C infection. 
Having defined the frequencies of these class II alleles in our chronic infection cohort, we 
next defined the role of DRB1 restricted HIV-specific CD4+ T cell responses on viral 
control. We observed increased levels of promiscuity, which is known to be a distinctive 
feature of antigen-specific CD4+ T cell recognition, with the presentation of a single peptide 
on numerous HLA class II variants expressed by various individuals (Figure 4.2). OLP-41 in 























































HLA- DRB 1 variants  
Figure 4.1. (A) Allele frequency among those individuals that displayed CD4 T cell responses 
in IFN-γ Elispot confirmatory assay (n=20). (B) Percentage frequency of various HLA-DRB1 
allele variants in CD4 T cell responders (n=20). (C) Percentage frequency of various HLA-





specific CD4+ T cells in clade B and C infection , exhibited the highest levels of promiscuity, 
restricted by 4 different HLA-DRB1 variants. The promiscuity in peptide-binding could be 
the open conformation of HLA class II, allowing for long peptides recognized by CD4+ T 
cells to extend beyond the HLA binding groove(Ranasinghe et al., 2013). In spite of the high 
degree of HLA-DRB1 binding promiscuity, marked differences was observed in the number 
of peptides that were restricted by each DRB1 variant (Figure 4.3A). Variants such as 
DRB1*03:01, DRB1*14:01 and DRB1*15:01 had no contribution to peptide restrictions as 
compared to DRB1*13:01 and DRB1*11:01 which had 9 and 4 HIV-specific peptides 
restricted respectively. It is important to note that these results could be biased by the number 
of subjects tested per variant, with a skewed testing of DRB1*13:01 due to aforementioned 
high allelic frequency in our cohort (Figure 4.3B).  
The data obtained is in concordance with results obtained in a previous study, using the same 
methods, in a cohort of clade B HIV infected individuals from Boston and San Francisco, by 
Ranasinghe et al. (2013). Further detailed analysis into the relationship between HLA-DRB1 
alleles and viral load need to be conducted to identify any associations between possession of 
a particular allele and disease outcome. Currently, the present data suggests an important role 
of HLA class II allele genetic associations with the functional responses of CD4+T cells. 




















Figure 4.2. HLA-DR restriction of HIV-specific CD4 T cell responses (indicating responses in the 




























































































Figure 4.3. (A) The number of HIV-specific peptides recognized by each HLA-DRB1 variant 






CHAPTER 5: OVERALL DISCUSSION AND FUTURE DIRECTIONS 
One of the major challenges for developing an efficacious HIV vaccine is the intrinsic 
diversity among circulating populations of HIV-1 in various geographical locations and the 
need to develop vaccines that can elicit enduring protective immunity across different strains. 
A growing body of literature has shown that effector CD4+T cells are an important factor in 
immune control of HIV-1 infection. However, precise details of CD4+ T cell contribution to 
immune protection against HIV have not been adequately defined and most of the existing 
data was predominantly generated in subtype B HIV-1 infection. Therefore, there is a gap in 
the information needed for designing an effective HIV vaccine with global utility. 
The role of CD4+ T cell responses in the control of numerous chronic viral infections has 
been well characterized, yet little is known about the role of these responses in HIV-1 
infection. Despite the significant role of CD4+ T cells in vaccine design and the course of 
natural infection, there have been very few studies that have characterized HIV-specific 
CD4+ T cells due to their preferential susceptibility to HIV-1 infection. Previous studies have 
suggested that the preservation of HIV-1 specific CD4+ T cell responses might be critical for 
the control of viral replication (Zhang and Bevan, 2011, Rosenberg et al., 1997). Therefore, 
this study and the work presented in this thesis aimed to assess the role of HIV-1 specific 
CD4+ T cell responses in HIV-1 infection. Furthermore, we wished to determine if the 
preservation of HIV-1 specific CD4+T cell responses might be a key factor in the overall 
immune responses in maintaining control over viral replication. 
The study set out to obtain an in depth understanding of the role of CD4+ T cells in clade C 
HIV-1 infection. This was addressed by firstly mapping immunodominance patterns and 
identifying specific targeted regions and peptide specificities using the IFN-γ ELISPOT assay 
in both acute and chronic clade C HIV-1 infection. While the ELISPOT assay allows for the 
evaluation of breadth and magnitude of T-cell responses elicited, its major limitation is that it 
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relays on only one T cell effector function, which is the ability of virus-specific cells to 
release IFN-γ upon antigen-peptide stimulation. Therefore, to better understand functional 
characteristics and cytokine secretion of HIV-specific CD4+ T cells we complimented the 
ELISPOT assay with intracellular cytokine staining which allows for simultaneous 
measurement of multiple cytokines, chemokines and cytotoxicity function. Having obtained 
an understanding of immunodominance and functional characteristics of HIV-specific CD4+ 
T cells, we next determined the role of host genetics i.e. HLA class II alleles on disease 
progression, assessing restriction characteristics at the HLA-DRB1 locus. There are 
numerous studies highlighting the importance of host genetics in determining overall 
outcome of an HIV-infected individual, however, most of these studies have looked at CD8+ 
T cells and HLA class I alleles (Gao et al., 2001, Pereyra et al., 2010). We hypothesised that 
HIV-1-specific CD4+ T cell responses and protective class II HLA alleles are important 
determinants of effective immunological control of HIV-1 infection and have been able to 
demonstrate this to some extent. 
Chapter 3 aimed to evaluate the immunodominant regions of the HIV-1 proteome targeted by 
HIV-specific CD4+ T cells during the first year of HIV-1 infection and to determine the 
evolution of these responses over time. Having previously alluded to well established 
knowledge that HIV preferentially infects and depletes HIV-specific CD4+ T cells, as well as 
to evidence suggesting that an effective CD8+ and antibody response is dependent on CD4+ 
T cell-mediated helper signals, it can be said that induction of HIV-specific CD4+ T cells 
during acute infection may in fact be a double-edged sword. As CD4+ T cells are the primary 
targets of HIV, increased generation of CD4+ T cell responses during the acute phase of HIV 
infection may cause an increase in the presence of target cells for HIV dissemination and 
hasten disease progression.  
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With various studies conducted on the specificities, breadth and magnitude of HIV-specific 
CD4+ T cell responses and the association with viremia in chronic infection, albeit in clade B 
HIV infection, detailed knowledge of these responses in early infection is poorly understood. 
We wanted to assess the development of HIV-specific CD4+ T cell responses in clade C 
infection during the acute phase, particularly the first year and map the progress of these 
responses over time. A diverse pattern of CD4+T-cell recognition across the HIV-1 proteome 
was evident during primary infection. We found that the dominant regions targeted during 
early infection were Gag and Pol, with Gag and Pol-specific responses found in 14 out of 15 
individuals tested. Furthermore, the overall HIV-specific CD4+ T cell responses during acute 
infection until 36 months post infection remained relatively stable over time in terms of 
frequency and magnitude. Previous studies looking at HIV-specific CD4+ T cell responses 
during acute HIV-1 infection are overall consistent with our findings (Schieffer et al., 2014). 
Possible explanations provided for the stability of frequency and dominance of HIV-specific 
CD4+ T cells over time include the shorter life span of these cells, resulting in the 
maintenance of stable levels due to a higher cell turnover rate (Brenchley et al., 2006, 
Schieffer et al., 2014). In addition, an interesting observation was the varied responses in the 
dominance and magnitude of HIV-specific CD4+ T cell responses among the 15 individuals. 
While 14/15 individuals displayed responses targeting more than one region of the proteome, 
some individuals showed increased responses while others showed decline in responses. The 
average response increased over time from 2 months post infection to approximately 11 
months post infection, decreasing once again 1 year post infection. These results are possibly 
linked to overall progression of the disease. Furthermore, they  are consistent with previous 
studies of primary infection, where a slight decrease, although not significant, was observed 
in the breadth and magnitude of HIV-specific CD4+ T cells over time (Oxenius et al., 2001, 
Lubong Sabado et al., 2009, Schieffer et al., 2014). The magnitude of HIV-specific CD4+ T 
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cell responses was observed to vary at different time points within each individual. This 
could be resultant of fluctuations in viremia as well as the increased destruction and 
impairment of HIV-specific CD4+ T cells as disease progresses.  
Gag-specific responses were shown to contribute largely to the overall total HIV-specific 
response. Given that previous studies in chronic infection indicated that increased Gag-
specific responses lead to better control of viremia , the results point to the importance of 
Gag-specific CD4+ T cell responses and a potential role in contributing to the control of HIV 
replication, with possible cytotoxic mechanisms (Ranasinghe et al., 2012, Soghoian et al., 
2012).  
An interesting observation in our study was the significant positive correlation we found with 
the combined magnitude of Gag and Pol-specific CD4+ T cell responses with viral load set 
point. The data suggests that the higher the Gag/Pol specific response, the higher viral load 
set point is. The higher viral load set point would indicate faster progression to disease, 
suggesting a potentially detrimental effect of the induction of Gag/Pol-specific CD4+ T cell 
responses in acute infection. Intriguingly, analysis of Gag and Pol individually, rather than 
combined showed no significant association with viral load for Gag responses and a 
significant positive correlation for Pol-specific responses. There was no association of Env-
specific CD4+ T cell responses and clinical outcome. Small sample size coupled with the fact 
that these responses were not examined at single epitope level may have biased our results. 
Overall, detailed analysis needs to be conducted to address the fluctuations of HIV-specific 
CD4+ T-cell responses during primary infection and the impact of these changes on disease 
progression.  
Despite the surprising positive associations between CD4+ T cell responses with viral load 
set point, the results do re-iterate that HIV-specific CD4+ T cells responding to various 
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antigens may have differing functional roles. In a matched cohort study characterizing 
protein-specific CD8+ T-cell immunodominance patterns during the first year of HIV-1 
infection, Gag-specific CD8+ T-cell responses were shown to be associated with viral 
control, where broad and persistent Gag-specific effector and central memory type CD8+ T-
cells were required for the maintenance of low viral load levels in primary infection(Radebe 
et al., 2014). Here, we show that Gag-specific CD4+ T cell responses are the most dominant 
and persist over time, thus suggesting an active role of Gag-specific CD4+ T-cell responses 
in acute infection. 
Overall, observations of CD4+ T cell responses during the acute phase of HIV infection in a 
clade C cohort indicate a role of Gag- and Pol-specific CD4+ T cell responses, having direct 
effects on viremia and on subsequent viral load set point. Furthermore, HIV-specific CD4+ T 
cell responses remain relatively stable in frequency and magnitude through which they are 
likely to mediate immune control of HIV viremia.  
Having examined the role of HIV-specific CD4+ T cells in acute clade C HIV infection, we 
next looked at chronic infection in order to obtain a better overall view of these responses. 
Therefore, chapter 3 further detailed the role of HIV-specific CD4+ T cell responses in 
chronic clade C HIV infection. The chapter defined the individual peptide sequences that are 
targeted by HIV-specific CD4+T cell responses in chronic HIV-1 infection, thus allowing a 
detailed identification of HIV-specific CD4+ T cells that are induced in natural HIV 
infection. Here, overlapping peptide pools that span every encoded HIV protein was used, 
allowing for a broader view of the overall immune response to HIV as well as its association 
to the various parameters associated with viral infection. Furthermore, immunodominance 
hierarchies of HIV-specific CD4+ T cell responses were elucidated.   
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We initially conducted a screening megamatrix ELISPOT analysis of 55 individuals from our 
chronic infection cohort. The results from this analysis indicated similar results as the 
previous analysis in the acute infection cohort, with Gag and Pol-specific CD4+ T cell 
responses being the most dominant. Gag-specific responses were observed in all individuals, 
with all demonstrating more than one detectable HIV-specific CD4+ T cell response. Once 
again, these results highlight the important role of Gag responses in immune mediated control 
of HIV-1 infection.   
We wanted to confirm these results and therefore analysed HIV-specific CD4+ T cell 
responses in 35 responders from the megamatrix screening, at the single peptide level. Here, 
we found that HIV-specific CD4+ T cell responses in chronic clade C infection dominantly 
target the Gag region, particularly the Gag p24 region (15/40 peptides). This region of Gag 
epitopes has been defined in immunodominant HIV-specific CD8+ T cell responses and has 
been previously been associated with viral control (Starr et al., 2003). The next most 
immunodominant regions targeted by HIV-specific CD4+ T cell responses were the Gag p17 
(9/40), Nef (7/40) and Gag p15 regions respectively (5/40).  The frequent targeting of Gag 
and the evident lack of responses to Env, Rev, Tat, Vif and Vpu are concordant with 
observations from studies of clade B CD4+ T cell epitope mapping (Addo et al., 2003). The 
reason for the more frequent targeting of the Gag region by CD4+ T cells, together with  
evidence of a role in controlling viremia demonstrated by other studies could be because of 
the high degree of conservancy of the protein (Freed, 1998), as well as the increased number 
of Gag molecules (1500) and the precursor Gag-Pol molecules (100) found in a single 
immature virus particle (Kurle et al., 2004). 
The epitope most targeted among the Gag epitopes, found in the Gag p24 region, was OLP 41 
(YVDRFFKTLRAEQATQDV). This particular epitope was observed to be frequently 
targeted in a matched cohort study in clade C infection (Ramduth et al., 2009), as well as in 
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clade B (Kaufmann et al., 2004, Ranasinghe et al., 2012), clade A/G HIV-1 infection and 
displayed a high degree of cross recognition between HIV-1 and HIV-2 infected individuals 
(Ondondo et al., 2008). Ramduth et al. (2009) showed that particular epitopes were able to 
mount equal magnitudeIFN-γCD4+ T cell responses against both clade B and C viruses. OLP 
41 in particular partially overlaps with the Major Homology Region (MHR), which is located 
at the C terminal dimerization  domain of p24, displaying significant homology amongst 
various retrovirus genre (Freed, 1998). Virus particles become defective in viral assembly, 
maturation and infectivity if mutations to MHR occur (Freed, 1998), with OLP 41 thus 
presenting as a potential valuable constituent  in an HIV vaccine, and needs to be further 
characterized.  
Ramduth et al. (2012) alludes to the point of using consensus clade C sequences to test for 
HIV-specific CD4+ T cell responses, stating that these sequences could possibly limit 
detection of antigen specific CD4+ T cell epitopes to more variable proteins. Therefore, the 
relative lack of responses in various proteins other than Gag may be due to use of autologous 
HIV-1 peptides as opposed to consensus sequences previously shown to significantly 
increase in detection of CD8+ T cell epitopes in clade B infection (Altfeld et al., 2003). Env-
specific responses were detectable in chronic clade B infection and even shown to have a 
negative impact on control of viremia and disease progression (Ranasinghe et al., 2012). 
However, our study together with a previous study in clade C infection (Ramduth et al., 
2009), demonstrated the lack of Env-specific CD4+ T cell responses in chronic HIV-1 
infection, thus the lack of detectable CD4+ T cell responses targeting Env need to be 
explored further.  
Despite demonstrating that Gag was the dominant target of HIV-1 specific CD4+ T cells, we 
could not detect an association between total HIV-specific responses as well as Gag-specific 
responses (both breadth and magnitude) and viral load in chronic HIV-1 infection. However, 
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reasoning for our results could be sample number, where only 20 of the individuals were 
studied compared to 373 and 93 subjects in previous studies. Furthermore these 
immunodominant responses are captured at a certain time point, whereas they could fluctuate 
in response to continued viral replication and possibly disappear at later time points. In 
addition, assay sensitivity and lack of use of autologous HIV peptides could also be 
contributing factors. Longitudinal analysis tracking these responses would assist in 
understanding the kinetics of HIV-specific CD4+ T cell responses in chronic infection.  
We undertook additional analysis to determine if differences exist between breadth of HIV-
specific CD4+ T cell responses in controllers and progressors. We observed no significant 
differences in CD4+ T cell responses between the two groups. These results are contrary to 
studies conducted in clade B infection where remarkable differences were observed between 
groups varying in their ability to control viral replication (Ranasinghe et al., 2012) . Clear 
differences observed in the study between controllers and progressors include a noticeable 
dominance of in the targeting of HIV-specific responses to the Env (gp120) region by 
progressors and the Gag (p24) region by controllers. This discrepancy may be due to the 
small number of controllers assesses in our study (N=5 controllers vs. N=15 progressors).  
We next wanted to assess further functional characteristics of CD4+ T cell responses in our 
chronic infection cohort using intracellular cytokine staining. These results, provides 
additional insight into the cytokine secretion profiles of CD4+ T cells in HIV infection.   
IFN-γ, IL-2 and TNF α were secreted by most of the individuals tested. IL-2 and IL-2/IFN-γ 
CD4+ T cell responses have been shown to be associated with the control of viremia (Younes 
et al., 2003, Boaz et al., 2002, Harari et al., 2005).This cytokine combination was rarely 
observed in our cohort, however this could be because of a skewing of the immune response 
in chronic infection to the dominant IFN-γ only producing effector memory phenotype (Day 
and Walker, 2003). In the ICS analysis as with previous ELISPOT data described above, 
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most of the responses were in the Gag region. The IFN-γ responses in some cases mirrored 
results obtained during the IFN-γ ELISPOT assay. However, some individuals that did not 
exhibit any HIV-specific CD4+ T cell responses during the ELISPOT assay displayed 
responses when tested by flow cytometry.  An example would be that responses were seen in 
the Env region during ICS as opposed to no responses observed through ELISPOT. This 
could suggest that these responses were maintained at a lower frequency and could not be 
detected by the regular ELISPOT assay. In addition peptide pools were used during the ICS 
analysis as compared to single peptides in the ELISPOT, therefore small, undetectable 
responses by ELISPOT could be detected during ICS. Furthermore, there are certain co-
stimulatory peptides required in order for a response to be exhibited, and this is possible 
when peptide pools are made use of. High levels of TNFα were observed in most individuals. 
TNFα is one of the greatly studied pro-inflammatory cytokines  because of the key role it 
plays in the origin and progression of HIV-1 (Bahia and Silakari, 2010). Higher levels of 
TNFα would be expected, as the host's immune-regulatory response influences HIV-1 
pathogenesis, triggering macrophages, monocytes and NK cells to produce TNFα (Alfano 
and Poli, 2005), resulting in a positive correlation between HIV-1 viremia and TNFα levels in 
the serum of HIV infected individuals. Further analysis into the polyfunctional capacity and 
memory phenotype of epitope specific CD4+ T cells need to be conducted to have a better 
overall view of the functional capacity and characteristics of HIV-specific CD4+ T cells.  
Lastly, we wanted to assess the impact of host genetic factors on HIV-1 specificCD4+ T cell 
responses in clade C HIV-1 infection. HLA class I molecules have been shown to 
significantly influence CD8+ T cell responses, yet only more recently has the influence of 
HLA class II molecules on CD4+ T cell responses been described (Julg et al., 2011, 
Ranasinghe et al., 2013), it is important to further characterize the role of host genetics in 
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viral control, with findings possibly being beneficial in vaccine design as these epitopes can 
induce responses amongst a wide array of HLA class II types. 
We assessed our chronic clade C HIV infected cohort to better understand the interaction 
between HIV-specific CD4+ T cell responses (previously elucidated in analysis mentioned 
above), HIV disease outcome and HLA class II alleles. The results obtained thus far are 
preliminary and provide a basis for subsequent analysis. We have found that the HLA-
DRB1*13 allele is the most frequent in our cohort, which is consistent with previous analysis 
conducted in clade C infection(Ndung'u et al., 2005). The DRB1*13 has been shown to 
confer protection in various other infections, including hepatitis B, where the allele is 
associated with better clearance and clinical disease outcome (Ramezani et al., 2008, Hohler 
et al., 1997, Kummee et al., 2007). Further studies in human papillomavirus (HPV) have 
indicated the DRB1*13 allele with conferring protection against the HPV-16 serotype, as 
well as being negatively correlated with the incidence of cervical carcinoma (Apple et al., 
1994, SastreGarau et al., 1996). In addition, DRB1*13 enrichment has been reported in 
individuals suffering from autoimmune diseases e.g. anti–citrullinated protein antibody–
negative rheumatoid arthritis (Lundstrom et al., 2009). Fainboim et al., (2001) proposes that 
the effective antigen presentation capacity of DRB1*13 bestows protection against viral 
infections and thus the observed effect on disease pathogenesis. It is unknown whether a 
more effective T cell response is needed to exhibit the observed associations or they are 
mediated through various other mechanisms.  
Our analysis of HLA-DRB1 restriction characteristics indicated high levels of promiscuity, 
with OLP-41, our most immunodominant peptide as indicated in results above, restricted by 4 
different HLA-DRB1 variants. The mechanism behind the higher levels of peptide-binding 
promiscuity could be the open conformation of HLA class II, allowing for long peptides 
recognized by CD4+ T cells to extend beyond the HLA binding groove (Ranasinghe et al., 
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2013). Our results indicate most of the HIV-specific CD4+ T cell responses from our 
ELISPOT analysis were made by individuals that possessed the DRB1*13 allele. However, 
this is most probably a causal effect of the allele frequency in our cohort. Our data provides 
further insight into the promiscuity and specificity of HLA-DR variants. 
Despite, the limited data shown on HLA-DRB1 restriction, this study is one of the first in 
clade C infection to assess the impact of HLA class II alleles on HIV disease progression. We 
hope to provide detailed evidence linking HLA class II genetic associations with functional 
CD4+ T cell responses, further emphasizing the important role HIV-specific CD4+ T cells 
play in the control of HIV infection. 
Study limitations: 
Having detailed the findings of the research undertaken for this research, one of the most 
important limitations was sample availability, where additional samples would allow for 
identification of immunodominance patterns of HIV-specific CD4+ T cell responses in acute 
infection at the single peptide level. Furthermore, more samples are needed to further identify 
responses in chronic infection and conclusively elucidate associations between viral load and 
disease outcome. In addition, to convincingly make conclusions regarding change of HIV-
specific CD4+ T cells over time, it would be important to follow the same individual from the 
acute to chronic phase of infection.  
Future directions of this study will include:  
 Further characterization of peptide sequences that induce HIV-specific T cell 
responses in longitudinal acute and chronic HIV infection.  
 More detailed definition of HLA class II restriction characteristics to identify genetic 
association with HIV control.  
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 Evaluation of HIV-specific CD4+ T cell activity as a direct contributor to the control 
of viremia or as a consequence of viral control. 
 Evaluation of the difference between cryopreserved and freshly isolated PBMC's to 
determine if long-term cryopreservation has detrimental effects on T cell IFN-γ 
responses. 
 Assessing the lack of Envelope responses in clade C HIV infection as studies have 
suggested that Env-specific T cells may be more critical to support neutralizing 
antibody production. 
 Further characterization of Pol versus Gag specific responses to examine if they differ 
in HIV susceptibility or other properties. 
 Use of MHC class II tetramers to quantify numbers of antigen-specific T cells and 
characterize functional differences of CD4+ T cells. 
In conclusion, Gag and Pol regions of the HIV proteome are most frequently targeted in acute 
HIV-1 infection, with CD4+ T cell targeting across the proteome remaining relatively stable 
over time. Furthermore, dominant HIV-1-specific CD4+ T cell responses are detectable 
against a limited number of epitopes in chronic HIV-1clade C infection. Epitopes in the Gag 
region are the most targeted by CD4+ T cell responses, with OLP 41 in the Gag p24 region 
being the most dominant epitope targeted. There were no significant associations observed 
between total and Gag-specific CD4+ T cell responses and contemporaneous viral load. 
Interestingly, responses in the envelope region were rarely targeted in chronic clade C 
infection as compared to multiple epitope targeting observed in this region in previous clade 
B studies. Functional analysis demonstrated that IFN-γ, IL-2 and TNFα were the most 
expressed cytokines by HIV-specific CD4+ T cells. The HLA class II DRB1 restriction in 
clade C HIV infected individuals showed epitope promiscuity, consistent with previous 
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studies in clade B infection. The HLA-DRB1*13:01 allele variant was seen in the highest 
frequencies in our cohort as well as being shown to restrict the highest number of HIV-
specific peptides. Together, the identification of immunodominant regions and the 
characterization of HIV-specific CD4+ T cell responses present during an effective immune 
response are likely to be important in characterizing clade C immunogenicity. Furthermore, 
our findings will inform studies aimed at elucidating the underlying mechanism by which 
CD4+ T cells modulate effective CD8+ T cell and B cell responses. This information may be 
critical to vaccine efforts designed to induce these responses, as well as potential therapeutic 






















To 500 ml RPMI (Sigma) add: 
50 ml heat inactivated and filter sterilized fetal calf serum 
5 ml L-glutamine 
5 ml Penstrep fungizone (100x) 
5 ml HEPES 
The medium was stored at 4ºC with an expiry time of 30 days. 
Phosphate Buffered Saline (PBS) 
One PBS tablet was dissolved in 100 ml distilled water. The solution was adjusted to a pH of 
7.2. Thereafter, autoclaved for 10 minutes at 115ºC. 
Blocking buffer 
10 ml heat inactivated and filter sterilized fetal calf serum was added to 1 liter of sterile PBS 
solution. The solution was stored at 4ºC with an expiry time of 30 days. 
Tris buffer 
12.1 g of powdered Tris was dissolved in distilled water. The pH was adjusted to 9.3 with 
concentrated HCl, bringing the volume to 1 liter. The solution was autoclaved for 10 minutes 





NBT (Nitro-Blue Tetrazolium Chloride) 
30 mg/l NBT powder was added to a 2 ml tube. 700 µl dimethylformamide (DMF) was added 
to the powder. Once completely dissolved, 300 µl sterile distilled water was added to the 
solution. The solution was stable at 4ºC for 7 days. 
BCIP (5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt) 
1 ml of DMF was added to 15 mg/ml of BCIP powder in a 2 ml tube to dissolve the powder. 
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